

DECLARATION OF ROSS D. MURRAY

CAMPBELL & WILLIAMS
J. COLBY WILLIAMS (5549)
710 South Seventh Street, Suite A
Las Vegas, Nevada 89101
Telephone: 702/382-5222
702/382-0540 (fax)
jcw@cwlawlv.com

Local Counsel for Lead Plaintiff
International Trading Group, Inc.

ROBBINS GELLER RUDMAN
& DOWD LLP
ELLEN GUSIKOFF STEWART
RYAN A. LLORENS
JEFFREY J. STEIN
JOHN M. KELLEY
SARAH A. FALLON
JESSICA E. ROBERTSON
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 619/231-1058
619/231-7423 (fax)
elleng@rgrdlaw.com
ryanl@rgrdlaw.com
jstein@rgrdlaw.com
jkelley@rgrdlaw.com
sfallon@rgrdlaw.com
jrobertson@rgrdlaw.com

Lead Counsel for Lead Plaintiff
International Trading Group, Inc.

UNITED STATES DISTRICT COURT

DISTRICT OF NEVADA

JOSE CHUNG LUO, Individually and on
Behalf of All Others Similarly Situated,

Plaintiff,

vs.

SPECTRUM PHARMACEUTICALS, INC., et
al.,

Defendants.

No. 2:21-cv-01612-CDS-BNW

CLASS ACTION

DECLARATION OF ROSS D. MURRAY
REGARDING NOTICE DISSEMINATION,
PUBLICATION, AND REQUESTS FOR
EXCLUSION RECEIVED TO DATE

1 I, ROSS D. MURRAY, declare and state as follows:

2 1. I am employed as a Vice President of Securities by Verita Global, located at 1
3 McInnis Parkway, Suite 250, San Rafael, California. The following statements are based on my
4 personal knowledge and information provided to me by others and if called to testify I could and
5 would do so competently.

6 2. Pursuant to the Court's June 16, 2025 Order Preliminarily Approving Settlement
7 and Providing for Notice (ECF 138) (the "Notice Order"), Verita Global was appointed as the
8 Claims Administrator in connection with the proposed Settlement of the above-captioned litigation
9 (the "Litigation"). I oversaw the notice services that Verita Global provided in accordance with
10 the Notice Order.

11 3. I submit this declaration in order to provide the Court and the parties to the
12 Litigation with information regarding: (i) mailing and emailing of the Court-approved Postcard
13 Notice (attached hereto as Exhibit A) and, if requested by potential Class Members, mailing of the
14 Notice of Pendency and Proposed Settlement of Class Action (the "Notice") and Proof of Claim
15 and Release form (the "Proof of Claim") (collectively, the "Claim Package," attached hereto as
16 Exhibit B); (ii) publication of the Summary Notice of Pendency and Proposed Settlement of Class
17 Action (the "Summary Notice"); (iii) establishment of the website and toll-free telephone number
18 dedicated to this Settlement; and (iv) the number of requests for exclusion from the Class received
19 to date by Verita Global.

20 **DISSEMINATION OF NOTICE**

21 4. Pursuant to the Notice Order, Verita Global is responsible for disseminating notice
22 of the Settlement to potential Class Members. The Class consists of all Persons who purchased or
23 otherwise acquired Spectrum Pharmaceuticals, Inc. ("Spectrum") common stock between March
24 7, 2018, and August 5, 2021, inclusive. Excluded from the Class are: (i) Defendants and members
25 of the Individual Defendants' immediate families; (ii) the officers and directors of Spectrum during
26 the Class Period, and members of their immediate families; (iii) the legal representatives, heirs,
27 successors, or assigns of any of the foregoing; and (iv) any entity in which any Defendant has or
28 had a controlling interest. Also excluded from the Class is any Person who properly excludes

1 himself, herself, itself, or themselves from the Class by submitting a valid and timely request for
2 exclusion.

3 5. Verita Global received a file via email from Spectrum's transfer agent, which
4 contained the names and addresses of potential Class Members. The list was reviewed to identify
5 and eliminate duplicate entries and incomplete data, resulting in a usable mailing list of 161 unique
6 names and addresses, and 22 email addresses. On July 3, 2025, Verita Global caused the Postcard
7 Notice to be sent by First-Class Mail to 161 potential Class Members, and via email to 22 potential
8 Class Members.

9 6. On July 3, 2025, as part of its normal mailing procedures, Verita Global mailed, by
10 First-Class Mail, Postcard Notices and cover letters to 256 brokerages, custodial banks, and other
11 institutions ("Nominee Holders") that hold securities in "street name" as nominees for the benefit
12 of their customers who are the beneficial owners of the securities. The Nominee Holders also
13 include a group of filers/institutions who have requested notification of every securities case.
14 These Nominee Holders are included in a proprietary database created and maintained by Verita
15 Global. In our experience, the Nominee Holders included in this proprietary database represent a
16 significant majority of the beneficial holders of securities. The cover letter accompanying the
17 Postcard Notices advised the Nominee Holders of the proposed Settlement and requested their
18 cooperation in forwarding the Postcard Notices to potential Class Members. In the more than four
19 decades that we have been providing notice and claims administration services in securities class
20 actions, we have found the majority of potential class members hold their securities in street name
21 and are notified through the Nominee Holders. Verita Global also mailed Postcard Notices and
22 cover letters to 4,413 institutions included on the U.S. Securities and Exchange Commission's
23 ("SEC") list of active brokers and dealers at the time of mailing. A sample of the cover letter
24 mailed to Nominee Holders and the institutions included on the SEC's list of active brokers and
25 dealers is attached hereto as Exhibit C.

26 7. On July 3, 2025, Verita Global also delivered electronic copies of the Postcard
27 Notice to 329 registered electronic filers who are qualified to submit electronic claims. These
28

1 filers are primarily institutions and third-party filers who typically file numerous claims on behalf
2 of beneficial owners for whom they act as trustees or fiduciaries.

3 8. As part of the notice program for this Settlement, on July 3, 2025, Verita Global
4 also delivered electronic copies of the Claim Package and Postcard Notice via email to be
5 published by the Depository Trust Company (“DTC”) on the DTC Legal Notice System (“LENS”).
6 LENS enables the participating bank and broker nominees to review the Claim Package and
7 Postcard Notice and contact Verita Global for copies of the Postcard Notice for their beneficial
8 holders.

9 9. Verita Global has acted as a repository for shareholder and nominee inquiries and
10 communications received in this Settlement. In this regard, Verita Global has forwarded the
11 Postcard Notice on request to nominees who purchased or otherwise acquired Spectrum common
12 stock during the Class Period for the beneficial interest of other persons. Verita Global has also
13 forwarded the Postcard Notice directly to beneficial owners upon receipt of the names and
14 addresses from such beneficial owners or nominees.

15 10. Following the initial mailing, Verita Global received 14 responses to the outreach
16 efforts described above, which included computer files containing a total of 6,756 names and
17 addresses and 183 email addresses of potential Class Members. In addition, 28 institutions
18 requested that Verita Global send them a total of 27,200 Postcard Notices for forwarding directly
19 to their clients. Verita Global also received four requests for Claim Packages from potential Class
20 Members. Verita Global has also mailed 94 Postcard Notices as a result of returned mail for which
21 new addresses were identified for re-mailing to those potential Class Members. Each of these
22 requests has been completed in a timely manner.

23 11. As of September 12, 2025, Verita Global has mailed or emailed a total of 39,414
24 Postcard Notices and four Claim Packages to potential Class Members and nominees. In addition,
25 one institution reported that they anticipated sending Postcard Notices via email to 14,370 potential
26 Class Members.

PUBLICATION OF THE SUMMARY NOTICE

12. In accordance with the Notice Order, on July 10, 2025, Verita Global caused the Summary Notice to be published in the national edition of *The Wall Street Journal* and transmitted over *Business Wire*, as shown in the confirmations of publication attached hereto as Exhibit D.

TELEPHONE HELPLINE AND WEBSITE

13. On July 3, 2025, Verita Global established and continues to maintain a case-specific, toll-free telephone helpline, 1-833-586-3555, to accommodate potential Class Member inquiries. The toll-free telephone number is set forth in the Postcard Notice, Notice, Proof of Claim, and on the case website. Verita Global has been and will continue to promptly respond to all inquiries to the toll-free telephone helpline. As of the date of this declaration, Verita Global has received 45 calls to the toll-free telephone helpline.

14. On July 3, 2025, Verita Global established and continues to maintain a website dedicated to this Settlement (www.SpectrumPharmaceuticalsSecuritiesSettlement.com) to provide additional information to Class Members and to provide answers to frequently asked questions. The web address was set forth in the Postcard Notice, Notice, Proof of Claim, and Summary Notice. The website includes information regarding the Litigation and the Settlement, including the exclusion, objection, and claim filing deadlines, and details about the Court's Settlement Hearing. Copies of the Notice, Proof of Claim, Stipulation, and Notice Order are posted on the website and are available for downloading. In addition, the website provides Class Members with the ability to submit their Proofs of Claim online. As of the date of this declaration, there have been 2,105 unique visitors to the website and 6,141 page views.

REQUESTS FOR EXCLUSION AND OBJECTIONS RECEIVED TO DATE


15. The Notice informs potential Class Members that written requests for exclusion from the Class are to be sent to Verita Global, such that they are postmarked or received no later than September 29, 2025.

16. The Notice also sets forth the information that must be included in each request for exclusion. As of the date of this declaration, Verita Global has received one request for exclusion, a redacted version of which is attached hereto as Exhibit E.

1 17. Although the Notice Order (and the Notice) provides that Class Members who wish
2 to file objections must file them with the Court and copy them to relevant counsel (rather than to
3 Verita Global), I also note for the sake of completeness that as of the date of this declaration Verita
4 Global has not received any objections.

5 I declare under penalty of perjury that the foregoing is true and correct and that this
6 declaration was executed this 12th day of September, 2025, at San Rafael, California.

7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28



ROSS D. MURRAY

EXHIBIT A

Spectrum Pharmaceuticals Securities Settlement
Claims Administrator
c/o Verita Global
P.O. Box 301171
Los Angeles, CA 90030-1171

LEGAL NOTICE

Luo v. Spectrum Pharmaceuticals, Inc., et al.,
No. 2:21-cv-01612-CDS-BNW

www.SpectrumPharmaceuticalsSecuritiesSettlement.com

Court-Ordered Legal Notice

(Forwarding Service Requested)

This notice contains important information about a securities class action settlement.

You may be entitled to a payment.
This notice may affect your legal rights.

Please read this notice carefully.

SPPS



Postal Service: Please Do Not Mark Barcode

SPPS - «Claim8»-«CkDig»

«FirstNAME» «LastNAME»

«Name1»

«Name2»

«Name3»

«Name4»

«Addr1» «Addr2»

«City», «State»«FProv» «Zip»«FZip»

«FCountry»



THIS POSTCARD PROVIDES ONLY LIMITED INFORMATION ABOUT THE SETTLEMENT.
VISIT WWW.SPECTRUMPHARMACEUTICALSSECURITIESSETTLEMENT.COM
OR CALL 1-833-586-3555 FOR MORE INFORMATION.

If you purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. ("Spectrum") common stock between March 7, 2018, and August 5, 2021, inclusive, you could be entitled to a payment from a proposed settlement (the "Settlement") reached in the above-captioned action (the "Litigation"). Your rights may be affected by this Litigation and the Settlement. A hearing will be held on October 20, 2025, at 10:00 a.m., at the United States District Court, District of Nevada, Lloyd D. George Federal Courthouse, 333 Las Vegas Boulevard South, Las Vegas, NV 89101 (the "Settlement Hearing"), before the Honorable Cristina D. Silva, to determine whether the proposed Settlement of the Litigation against defendants Spectrum, Joseph W. Turgeon, Kurt A. Gustafson, Francois J. Lebel, and Thomas J. Riga (together, "Defendants") for \$15.95 million in cash and the Plan of Allocation should be approved as fair, reasonable, and adequate; whether the Litigation should be dismissed with prejudice against Defendants, as set forth in the Stipulation of Settlement (the "Stipulation") filed with the Court; and whether Lead Counsel's application for an award of attorneys' fees of up to 30% of the Settlement Amount, and expenses not to exceed \$200,000, plus interest on both amounts, and an award to Lead Plaintiff, should be granted.

If approved, the Settlement will resolve a putative class action lawsuit alleging that, in violation of the U.S. federal securities laws, Defendants misled investors by making materially false and misleading statements and failing to disclose material information, which caused Spectrum's stock to trade at artificially inflated prices until the nature of the alleged wrongdoing was revealed, causing Spectrum's stock price to fall. Defendants deny the allegations and any liability or wrongdoing of any kind. For a full description of the proposed Settlement and your rights, and to make a claim, you may obtain the Stipulation, long-form Notice of Pendency and Proposed Settlement of Class Action ("Notice"), and the Proof of Claim and Release form ("Claim Form") by visiting the website: www.SpectrumPharmaceuticalsSecuritiesSettlement.com (the "Website"), or you may request copies of the documents from the Claims Administrator by: (i) mail: *Spectrum Pharmaceuticals Securities Settlement*, Claims Administrator, c/o Verita Global, P.O. Box 301171, Los Angeles, CA 90030-1171, or (ii) toll-free call: 1-833-586-3555.

To qualify for a payment from the Settlement, you must submit a valid Claim Form, with supporting documentation, postmarked or submitted online no later than October 1, 2025. Your pro rata share of the Settlement will depend on the number of valid claims, and the number, size, and timing of your transactions in Spectrum common stock. The estimated average distribution per share of Spectrum common stock is approximately \$0.06, before deducting any Court-approved fees and expenses. Your actual share of the Settlement will be determined pursuant to the proposed Plan of Allocation set forth in the Notice, or other plan approved by the Court.

You will be bound by any judgment or order entered in the Litigation, regardless of whether you submit a Claim Form, unless you exclude yourself from the Class. If you exclude yourself from the Class, you cannot get money from this Settlement. If you are a Class Member and do not exclude yourself from the Class, you may object to the proposed Settlement, Plan of Allocation, and/or request for award of attorneys' fees and expenses and award to Lead Plaintiff no later than September 29, 2025. The long-form Notice and the Website explain how to exclude yourself from the Class or how to object.

Lead Plaintiff and the Class are represented by Lead Counsel: Ellen Gusikoff Stewart, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, settlementinfo@rgrdlaw.com. You may, but do not have to, attend the Settlement Hearing to be heard. The Court reserves the right to hold the Settlement Hearing telephonically or by other virtual means and/or change its date and/or time. Please check the Website for updates.

EXHIBIT B

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

JOSE CHUNG LUO, Individually and on Behalf of)	No. 2:21-cv-01612-CDS-BNW
All Others Similarly Situated,)	<u>CLASS ACTION</u>
)	
Plaintiff,)	NOTICE OF PENDENCY AND PROPOSED
)	SETTLEMENT OF CLASS ACTION
vs.)	
SPECTRUM PHARMACEUTICALS, INC., et al.,)	
)	
Defendants.)	
)	

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SPECTRUM PHARMACEUTICALS, INC. ("SPECTRUM") COMMON STOCK BETWEEN MARCH 7, 2018, AND AUGUST 5, 2021, INCLUSIVE (THE "CLASS PERIOD")

PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY. YOUR RIGHTS MAY BE AFFECTED BY PROCEEDINGS IN THIS LITIGATION. PLEASE NOTE THAT IF YOU ARE A CLASS MEMBER, YOU MAY BE ENTITLED TO SHARE IN THE PROCEEDS OF THE SETTLEMENT DESCRIBED IN THIS NOTICE. TO CLAIM YOUR SHARE OF THE SETTLEMENT PROCEEDS, YOU MUST SUBMIT A VALID PROOF OF CLAIM AND RELEASE FORM ("PROOF OF CLAIM") **POSTMARKED OR SUBMITTED ONLINE (AT WWW.SPECTRUMPHARMACEUTICALSSECURITIESSETTLEMENT.COM) ON OR BEFORE OCTOBER 1, 2025.**

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION.

This Notice of Pendency and Proposed Settlement of Class Action ("Notice") has been issued pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Nevada (the "Court"). The purpose of this Notice is to inform you of: (i) the pendency of this class action (the "Litigation") between International Trading Group, Inc. ("Lead Plaintiff") and Spectrum,¹ Joseph W. Turgeon, Kurt A. Gustafson, Francois J. Lebel, and Thomas J. Riga (collectively, "Defendants"); (ii) the proposed \$15.95 million cash settlement reached therein (the "Settlement"); and (iii) the hearing (the "Settlement Hearing") to be held by the Court to consider the fairness, reasonableness, and adequacy of the Settlement, as set forth in the Stipulation of Settlement dated May 9, 2025 (the "Stipulation"), by and between Lead Plaintiff and Defendants (the "Parties" or "Settling Parties"). This Notice describes what steps you may take in relation to the Settlement and this class action.²

This Notice is not intended to be, and should not be construed as, an expression of any opinion by the Court with respect to the truth of the allegations in the Litigation as to any of the Defendants or the merits of the claims or defenses asserted by or against the Defendants. This Notice is solely to advise you of the pendency of the Litigation, the proposed Settlement of the Litigation, and your rights in connection therewith.

¹ Spectrum was acquired by Assertio Holdings, Inc. on July 31, 2023.

² All capitalized terms used in this Notice that are not otherwise defined herein shall have the meanings provided in the Stipulation, which is available on the website www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

YOUR LEGAL RIGHTS AND OPTIONS IN THIS SETTLEMENT	
SUBMIT A PROOF OF CLAIM	The only way to be eligible to receive a payment from the Settlement. Proofs of Claim must be postmarked or submitted online on or before October 1, 2025.
EXCLUDE YOURSELF FROM THE CLASS	Get no payment. This is the only option that <i>potentially</i> allows you to ever be part of any other lawsuit against the Defendants or any other Released Defendant Parties about the legal claims being resolved by this Settlement. Should you elect to exclude yourself from the Class you should understand that Defendants and the other Released Defendant Parties will have the right to assert any and all defenses they may have to any claims that you may seek to assert, including, without limitation, the defense that any such claims are untimely under applicable statutes of limitations and statutes of repose. Requests for exclusion must be postmarked on or before September 29, 2025.
OBJECT	Write to the Court about why you do not like the Settlement, the Plan of Allocation, and/or the request for attorneys' fees and expenses. You will still be a Member of the Class. Objections must be received by the Court and counsel on or before September 29, 2025. If you submit a written objection, you may (but do not have to) attend the Settlement Hearing.
GO TO THE SETTLEMENT HEARING ON OCTOBER 20, 2025	Ask to speak in Court about the fairness of the Settlement, the Plan of Allocation, and/or the request for attorneys' fees and expenses. Requests to speak at the Settlement Hearing must be received by the Court and counsel on or before September 29, 2025.
DO NOTHING	Receive no payment. You will, however, still be a Member of the Class, which means that you give up your right to ever be part of any other lawsuit against the Defendants or any other Released Defendant Parties about the legal claims being resolved by this Settlement and you will be bound by any judgments or orders entered by the Court in the Litigation.

SUMMARY OF THIS NOTICE

Statement of Class Recovery

Pursuant to the Settlement described herein, a \$15.95 million cash settlement fund has been established. Based on Lead Plaintiff's estimate of the number of allegedly damaged shares eligible to recover under the Settlement, the average distribution per share of Spectrum common stock under the Plan of Allocation is approximately \$0.06, before deduction of any taxes on the income earned on the Settlement Amount, notice and administration costs, and the attorneys' fees and expenses as determined by the Court. **Class Members should note, however, that this is only an estimate.** A Class Member's actual recovery will be a proportion of the Net Settlement Fund determined by that claimant's claim as compared to the total claims of all Class Members who submit acceptable Proofs of Claim. An individual Class Member may receive more or less than this estimated average distribution amount. Please see the Plan of Allocation set forth and discussed at pages 11 through 15 below for more information on the calculation of your claim.

Statement of Potential Outcome of Case

The Settling Parties disagree on both liability and damages and do not agree on the amount of damages that would be recoverable if the Class prevailed on each or any claim alleged. Defendants deny that they are liable to the Class and deny that the Class has suffered any damages. The issues on which the Settling Parties disagree are many, but include: (1) whether Defendants engaged in conduct that would give rise to any liability to the Class under the federal securities laws; (2) whether Defendants have valid defenses to any such claims of liability; (3) the appropriate economic model for determining the amount by which the price of Spectrum common stock was allegedly artificially inflated (if at all) during the relevant period; and (4) the amount, if any, by which the price of Spectrum common stock was allegedly artificially inflated (if at all) during the relevant period.

Statement of Attorneys' Fees and Expenses Sought

Since the Litigation's inception, Lead Plaintiff's Counsel have expended considerable time and effort in the prosecution of this Litigation on a wholly contingent basis and have advanced the expenses of the Litigation in the expectation that if they were successful in obtaining a recovery for the Class, they would be paid from such recovery. Lead Counsel will apply to the Court on behalf of all Lead Plaintiff's Counsel for an award of attorneys' fees not to exceed 30% of the Settlement Amount, plus expenses not to exceed \$200,000, plus interest earned on both amounts at the same rate as earned by the Settlement Fund. If the amounts requested are approved by the Court, the average cost per Spectrum common share will be approximately \$0.02. In addition, Lead Plaintiff may seek an award not to exceed \$12,000 in connection with its representation of the Class.

Further Information

For further information regarding the Litigation, this Notice, or to review the Stipulation, please contact the Claims Administrator toll-free at 1-833-586-3555, or visit the website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

You may also contact a representative of counsel for the Class: Greg Wood, Shareholder Relations, Robbins Geller Rudman & Dowd LLP, 655 West Broadway, Suite 1900, San Diego, CA 92101, 1-800-449-4900, settlementinfo@rgdlaw.com.

Please Do Not Call the Court or Defendants with Questions About the Settlement.

Reasons for the Settlement

Lead Plaintiff's principal reason for entering into the Settlement is the benefit to the Class now, without further risk or the delays inherent in continued litigation. The cash benefit under the Settlement must be considered against the significant risk that a smaller recovery – or, indeed, no recovery at all – might be achieved after contested motions, trial, and likely appeals, a process that could last several years into the future. For Defendants, who have denied and continue to deny all allegations of liability, fault, or wrongdoing whatsoever, the principal reason for entering into the Settlement is to eliminate the uncertainty, risk, costs, and burdens inherent in any litigation, especially in complex cases such as this Litigation. Defendants have concluded that further conduct of this Litigation could be protracted and distracting.

BASIC INFORMATION

1. What is the purpose of this Notice?

The Court has directed the issuance of this Notice to inform potential Class Members about the Litigation and the proposed Settlement and their options in connection therewith before the Court rules on the Settlement. Additionally, Class Members have the right to understand how this class action lawsuit may generally affect their legal rights.

This Notice explains the class action lawsuit, the Settlement, Class Members' legal rights in connection with the Settlement, what benefits are available, who is eligible for them, and how to get them.

The Court in charge of the Litigation is the United States District Court for the District of Nevada, and the case is known as *Luo v. Spectrum Pharmaceuticals, Inc., et al.*, No. 2:21-cv-01612-CDS-BNW. The case has been assigned to the Honorable Cristina D. Silva. The entity representing the Class is the "Lead Plaintiff," and the company and individuals it sued and who have now settled are called the "Defendants."

The issuance of this Notice is not an expression of any opinion by the Court concerning the merits of any claim in the Litigation, and the Court still has to decide whether to approve the Settlement. If the Court approves the Settlement and a plan of allocation, then payments to Authorized Claimants will be made after any appeals are resolved and after the completion of all claims processing. Please be patient, as this process can take some time to complete.

2. What is this lawsuit about?

The Litigation is currently pending before Judge Cristina D. Silva in the United States District Court for the District of Nevada (the “Court”). The initial complaint in the Litigation was filed on August 31, 2021. On July 28, 2022, the Court appointed International Trading Group, Inc. as Lead Plaintiff and Robbins Geller Rudman & Dowd LLP as Lead Counsel.

On September 26, 2022, Lead Plaintiff filed the Amended Consolidated Class Action Complaint (the “Complaint”) alleging violations of §§10(b), 20(a), and 20A of the Securities Exchange Act of 1934 (the “Exchange Act”). On November 30, 2022, Defendants moved to dismiss the Complaint. Lead Plaintiff filed its opposition to the motion on January 27, 2023, and Defendants filed their reply on February 27, 2023. The Court held a hearing on Defendants’ motion to dismiss on February 6, 2024, and granted the motion without prejudice.

On March 29, 2024, Lead Plaintiff filed the Second Amended Consolidated Class Action Complaint (the “Amended Complaint”). Defendants moved to dismiss the Amended Complaint on May 13, 2024. Lead Plaintiff filed its opposition to the motion to dismiss on June 27, 2024, and Defendants filed their reply brief on July 22, 2024. On October 7, 2024, the Court issued an order granting in part and denying in part Defendants’ motion to dismiss the Amended Complaint.

On October 23, 2024, Lead Plaintiff and Defendants filed their joint proposed discovery plan and proposed schedule, which was entered on October 24, 2024.

The Court’s October 7, 2024 Order also referred the case to a magistrate judge for a mandatory settlement conference pursuant to Local Rule 16-5. Magistrate Judge Brenda Weksler scheduled a settlement conference for January 22, 2025.

The Parties thereafter agreed to engage a private mediator and on January 10, 2025, Magistrate Judge Weksler entered an order granting the Parties’ Joint Motion to Abate the Settlement Conference and Amend Scheduling Order.

Lead Plaintiff and Defendants participated in a voluntary confidential mediation session with David M. Murphy (of Phillips ADR), an experienced mediator, on March 20, 2025. The mediation session was preceded by the submission and exchange of opening and reply mediation statements by both Lead Plaintiff and Defendants. The Parties engaged in good-faith negotiations, but did not reach a settlement at the mediation session. Following additional settlement discussions with Mr. Murphy, on March 26, 2025, the Parties accepted a mediator’s proposal to settle the Litigation in return for a cash payment of \$15.95 million to be paid by Defendants and/or their insurers on behalf of Defendants for the benefit of the Class, subject to the negotiation of the terms of a stipulation of settlement and approval by the Court. The Stipulation (together with the Exhibits thereto) was duly executed by counsel for Lead Plaintiff and for the Defendants on behalf of their respective clients, and reflects the final and binding agreement among the Settling Parties.

3. Why is there a settlement?

The Court has not decided in favor of Defendants or Lead Plaintiff. Instead, both sides agreed to the Settlement to avoid the distraction, costs, and risks of further litigation, and Lead Plaintiff agreed to the Settlement in order to ensure that Class Members will receive compensation.

If there were no Settlement and Lead Plaintiff failed to establish any essential legal or factual element of its remaining claims against Defendants, neither Lead Plaintiff nor the other Members of the Class would recover anything from Defendants. Also, if Defendants proved any of their defenses at summary judgment, trial, or on appeal, the Class could recover substantially less than the amount provided in the Settlement, or nothing at all.

WHO IS IN THE SETTLEMENT**4. How do I know if I am a Member of the Class?**

The Court directed that everyone who fits this description is a Class Member: all Persons who purchased or otherwise acquired Spectrum common stock between March 7, 2018, and August 5, 2021, inclusive. Excluded from the Class are: (i) Defendants and members of the Individual Defendants’ immediate families; (ii) the officers and directors of Spectrum during the Class Period, and members of their immediate

families; (iii) the legal representatives, heirs, successors, or assigns of any of the foregoing; and (iv) any entity in which any Defendant has or had a controlling interest. Also excluded from the Class is any Person who properly excludes himself, herself, itself, or themselves from the Class by submitting a valid and timely request for exclusion. To the extent any Spectrum employee benefit plan receives a distribution from the Net Settlement Fund, no portion shall be allocated to any Person who is excluded from the Class by definition.

Please Note: Receipt of this Notice or the Postcard Notice does not mean that you are a Class Member or that you will be entitled to receive a payment from the Settlement. If you are a Class Member and you wish to be eligible to participate in the distribution of the proceeds from the Settlement, you are required to submit a Proof of Claim and the required supporting documentation as set forth therein postmarked or submitted online on or before October 1, 2025.

5. What if I am still not sure if I am included in the Class?

If you are still not sure whether you are included in the Class, you can ask for free help. You can contact the Claims Administrator toll-free at 1-833-586-3555, or you can fill out and return the Proof of Claim to see if you qualify.

THE SETTLEMENT BENEFITS – WHAT YOU GET

6. What does the Settlement provide?

The Settlement provides that, in exchange for the release of the Released Plaintiff's Claims (defined below) and dismissal of the Litigation, Defendants have agreed to pay or cause to be paid \$15.95 million in cash to be distributed after Taxes, Tax Expenses, Notice and Administration Expenses, and Court approved attorneys' fees and expenses, *pro rata*, to Class Members who send in a valid Proof of Claim pursuant to the Court-approved Plan of Allocation. The Plan of Allocation is described in more detail at the end of this Notice.

7. How much will my payment be?

Your share of the Net Settlement Fund will depend on several things, including the total dollar amount of claims represented by the valid Proofs of Claim that Class Members submit, compared to the dollar amount of your claim, all as calculated under the Plan of Allocation discussed below.

HOW YOU GET A PAYMENT – SUBMITTING A PROOF OF CLAIM

8. How can I get a payment?

To be eligible to receive a payment from the Settlement, you must submit a Proof of Claim. A Proof of Claim may be downloaded at www.SpectrumPharmaceuticalsSecuritiesSettlement.com. Read the instructions contained in the Proof of Claim carefully, fill out the Proof of Claim, include all the documents the form asks for, sign it, and **mail** (to *Spectrum Pharmaceuticals Securities Settlement*, Claims Administrator, c/o Verita Global, Claims Administrator, P.O. Box 301171, Los Angeles, CA 90030-1171) **or submit it online at www.SpectrumPharmaceuticalsSecuritiesSettlement.com so that it is postmarked or received no later than October 1, 2025.**

9. When will I get my payment?

The Court will hold a Settlement Hearing on October 20, 2025, at 10:00 a.m., to decide whether to approve the Settlement. If the Court approves the Settlement, there might be appeals. It is always uncertain whether appeals can be resolved, and if so, how long it will take to resolve them. It also takes time for all the Proofs of Claim to be processed. Please be patient.

10. What am I giving up to get a payment or to stay in the Class?

If you are a Class Member, unless you timely and validly exclude yourself from the Class, you will remain a Class Member, and that means you cannot sue, continue to sue, or be part of any other lawsuit against Defendants or the Released Defendant Parties about the Released Plaintiff's Claims (as defined below) in this Litigation. It also means that all of the Court's orders will apply to you and legally bind you. If you remain a Class Member, and if the Settlement is approved, you will give up all "Released Plaintiff's Claims" (as defined below), including "Unknown Claims" (as defined below), against the "Defendants' Released Persons" (as defined below):

- "Released Plaintiff's Claims" means all claims and causes of action of every nature and description, whether known or unknown, including Unknown Claims (as defined below), whether arising under federal, state, local, common, statutory, administrative or foreign law, or any other law, rule or regulation, at law or inequity, whether class or individual in nature, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, that Lead Plaintiff or any other Class Member has or could have asserted in any court or forum, based on, arising out of, or in connection with: (i) any purchase or acquisition of Spectrum common stock during the period between March 7, 2018, and August 5, 2021, inclusive; and (ii) the allegations, acts, facts, matters, occurrences, transactions, disclosures, filings, representations, statements, or omissions that were or could have been alleged by Lead Plaintiff or any other Member of the Class in the Litigation. Released Plaintiff's Claims do not include: (i) any claims related to the enforcement of the Settlement; (ii) any claims asserted in the actions styled: (a) *Christiansen v. Spectrum Pharmaceuticals, Inc.*, Case No. 1:22-cv-10292-VEC (S.D.N.Y.); (b) *Ayoub v. Spectrum Pharmaceuticals, Inc.*, Case No. 1:24-cv-8138-VEC (S.D.N.Y.); (c) *Changyoung Jung, derivatively on behalf of Spectrum Pharmaceuticals, Inc. & Assertio Holdings, Inc. v. Francois Lebel, et al.*, Case No. 2024-0821 (Del. Ch.); or (d) *Changyoung Jung, derivatively on behalf of Spectrum Pharmaceuticals, Inc. & Assertio Holdings, Inc. v. Joseph Turgeon, et al.*, Case No. 2024-0822 (Del. Ch.); (iii) any claims arising out of ERISA; or (iv) any claims of any Person who or which submits a request for exclusion from the Class that is accepted by the Court.
- "Released Defendants' Claims" means any and all claims and causes of action of every nature and description whatsoever, including both known claims and Unknown Claims (as defined below), whether arising under federal, state, common, or foreign law, against Releasing Plaintiff Parties (as defined below) that arise out of or relate in any way to the institution, prosecution, or settlement of the claims against Defendants in the Litigation. Released Defendants' Claims do not include: (i) any claims relating to the enforcement of the Settlement; or (ii) any claims against any Person who or which submits a request for exclusion from the Class that is accepted by the Court.
- "Released Defendant Party" or "Released Defendant Parties" or "Defendants' Released Persons" mean any or all of Defendants and/or any or all of their current, former, or future parents, affiliates, subsidiaries, business units, divisions, or controlling shareholders; and each and all of their and Defendants' respective current, former, or future officers, directors, employees, members, managers, partners, principals, controlling shareholders, agents, advisors, accountants, auditors, insurers, reinsurers, and attorneys; and the predecessors, successors, estates, assigns, assignees, immediate family members, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives of each of them, in their capacities as such.

- “Releasing Plaintiff Party” or “Releasing Plaintiff Parties” mean Lead Plaintiff, all other plaintiffs in the Litigation, their respective attorneys, and all other Class Members, and each and all of their respective current, former, or future parents, affiliates, subsidiaries, business units, divisions, or controlling shareholders; each and all of their respective current, former, or future officers, directors, employees, members, managers, partners, principals, controlling shareholders, agents, advisors, accountants, auditors, insurers, reinsurers, and attorneys; and the predecessors, successors, estates, assigns, assignees, immediate family members, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representative of each of them, in their capacities as such.
- “Unknown Claims” means: (a) any and all Released Plaintiff’s Claims that any of the Releasing Plaintiff Parties do not know or suspect to exist in his, her, or its favor at the time of the release of such claims; and (b) any and all Released Defendants’ Claims that any of the Released Defendant Parties do not know or suspect to exist in his, her, or its favor at the time of the release of such claims, which, if known by him, her, or it, might have affected his, her, or its decision(s) with respect to this Settlement. With respect to: (a) any and all Released Plaintiff’s Claims against the Released Defendant Parties; and (b) any and all Released Defendants’ Claims against the Releasing Plaintiff Parties, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive, and each Releasing Plaintiff Party and Released Defendant Party shall be deemed to have, and by operation of the Judgment shall have expressly waived, any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or principle of common law or foreign law, that is similar, comparable, or equivalent to California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties shall fully, finally, and forever expressly waive any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or any other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542. The Releasing Plaintiff Parties and Released Defendant Parties acknowledge that they may hereafter discover facts, legal theories, or authorities in addition to or different from those which he, she, it, or their counsel now knows or believes to be true with respect to the subject matter of the Released Plaintiff’s Claims or Released Defendants’ Claims, but: (a) the Releasing Plaintiff Parties shall expressly, fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Releasing Plaintiff Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Plaintiff’s Claims against the Released Defendant Parties, known or unknown, suspected or unsuspected, contingent or non-contingent, accrued or unaccrued, whether or not concealed or hidden, which now exist, or heretofore have existed, or may hereafter exist, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law, or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities; and (b) the Released Defendant Parties shall expressly, fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Released Defendant Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Defendants’ Claims against Lead Plaintiff, the Class, and Lead Plaintiff’s Counsel, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or

equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. The Settling Parties acknowledge, and the Releasing Plaintiff Parties and Released Defendant Parties shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

EXCLUDING YOURSELF FROM THE CLASS

If you do not want to participate in this Settlement, and you want to keep the right to potentially sue Defendants and the other Released Defendant Parties, on your own, about the claims being released by the Settlement, then you must take steps to remove yourself from the Class. This is called excluding yourself – or is sometimes referred to as “opting out.” If you are requesting exclusion from the Class because you want to bring your own lawsuit based on the matters alleged in this Litigation, you may want to consult an attorney and discuss whether any individual claim that you may wish to pursue would be time-barred by the applicable statutes of limitation or repose. If requests for exclusion exceed a certain amount, as set forth in a separate confidential agreement between the Settling Parties, Defendants shall have, in their discretion, the option to terminate the Settlement in accordance with the procedures set forth in the Supplemental Agreement.

11. How do I get out of the Class and the proposed Settlement?

To exclude yourself from the Class and the Settlement, you must send a letter by First-Class Mail stating that you “request exclusion from the Class in the *Spectrum Pharmaceuticals Securities Settlement*.” Your letter must include your purchases, acquisitions, and sales of Spectrum common stock during the Class Period, including the dates and number of shares of Spectrum common stock purchased, acquired, or sold, and the price paid for each such purchase or acquisition and received for each such sale. In addition, you must include your name, address, email address, telephone number, and your signature. You must mail your exclusion request so that it is **postmarked no later than September 29, 2025** to:

Spectrum Pharmaceuticals Securities Settlement
Claims Administrator
c/o Verita Global
EXCLUSIONS
P.O. Box 5100
Larkspur, CA 94977-5100

If you ask to be excluded, you will not get any payment from the Settlement, and you cannot object to the Settlement. You will not be legally bound by anything that happens in this lawsuit, and you may be able to sue Defendants and the other Released Defendant Parties about the Released Plaintiff’s Claims in the future, if such claims are not time-barred.

12. If I do not exclude myself, can I sue Defendants and the other Released Defendant Parties for the same thing later?

No. Unless you exclude yourself from the Class, you give up any rights you may potentially have to sue Defendants and the other Released Defendant Parties for any and all Released Plaintiff’s Claims. If you have a pending lawsuit against any of the Released Defendant Parties, speak to your lawyer in that case immediately. You must exclude yourself from the Class in this Litigation to continue your own lawsuit. Remember, the exclusion deadline is September 29, 2025.

13. If I exclude myself, can I get money from the proposed Settlement?

No. If you exclude yourself from the Class, you should not send in a Proof of Claim to ask for any money from the Settlement. But you may have the right to potentially sue or be part of a different lawsuit against Defendants and/or the Released Defendant Parties.

THE LAWYERS REPRESENTING YOU

14. Do I have a lawyer in this case?

The Court ordered that the law firm of Robbins Geller Rudman & Dowd LLP represents the Class Members, including you. These lawyers are called Lead Counsel. If you want to be represented by your own lawyer, you may hire one at your own expense.

15. How will the lawyers be paid?

Lead Counsel, on behalf of Lead Plaintiff's Counsel, will apply to the Court for an award of attorneys' fees not to exceed 30% of the Settlement Amount and for expenses, costs, and charges in an amount not to exceed \$200,000 in connection with the Litigation, plus interest on such fees and expenses at the same rate as earned by the Settlement Fund. In addition, Lead Plaintiff may seek reimbursement for its time and expenses incurred in representing the Class. Such sums as may be approved by the Court will be paid from the Settlement Fund.

OBJECTING TO THE SETTLEMENT

You can tell the Court that you do not agree with the Settlement or any part of it.

16. How do I tell the Court that I object to the proposed Settlement?

If you are a Class Member, you can comment on or object to the proposed Settlement, the proposed Plan of Allocation, and/or Lead Counsel's fee and expense application. You can write to the Court setting out your comment or objection. The Court will consider your views. To comment or object, you must send a signed letter saying that you wish to comment on or object to the proposed Settlement in the *Spectrum Pharmaceuticals Securities Settlement*. Include your name, address, email address, telephone number, and your signature (even if you are represented by counsel), identify the date(s), price(s), and number of shares of Spectrum common stock purchased, acquired, or sold during the Class Period, and state with specificity your comments or the reasons why you object to the Settlement, Plan of Allocation, and/or fee and expense application, including any legal and evidentiary support for such objection. Any objection must state whether it applies only to the objector, to a specific subset of the Class, or to the entire Class. In addition, the objector must identify all class action settlements to which the objector or his, her, or its counsel have previously objected. You must also include copies of documents demonstrating your purchases, other acquisitions, and/or sales of Spectrum common stock during the Class Period. Your comment or objection must be filed with the Court and mailed or delivered to each of the following addresses such that it is **received no later than September 29, 2025**:

COURT

CLERK OF THE COURT
UNITED STATES
DISTRICT COURT
DISTRICT OF NEVADA
Lloyd D. George Federal Courthouse
333 Las Vegas Boulevard South
Las Vegas, NV 89101

LEAD COUNSEL

ROBBINS GELLER RUDMAN
& DOWD LLP
Attn: Ellen Gusikoff Stewart
655 West Broadway
Suite 1900
San Diego, CA 92101

DEFENDANTS' COUNSEL

BAKER BOTTS L.L.P.
Attn: John B. Lawrence
2001 Ross Avenue
Suite 900
Dallas, TX 75201

17. What is the difference between objecting and excluding?

Objecting is simply telling the Court that you do not like something about the Settlement. You can object **only** if you stay in the Class.

Excluding yourself is telling the Court that you do not want to be paid and do not want to release any claims you think you may have against Defendants and the other Released Defendant Parties. If you exclude yourself from the Class, you cannot object to the Settlement because it does not affect you.

THE COURT'S SETTLEMENT HEARING

The Court will hold a hearing to decide whether to approve the proposed Settlement. You may attend the hearing and speak, but you do not have to.

18. When and where will the Court decide whether to approve the proposed Settlement?

The Court will hold a Settlement Hearing at **10:00 a.m., on October 20, 2025**, in the Courtroom of the Honorable Cristina D. Silva, at the United States District Court for the District of Nevada, Lloyd D. George Federal Courthouse, 333 Las Vegas Boulevard South, Las Vegas, NV 89101. At the hearing, the Court will consider whether the Settlement and the Plan of Allocation are fair, reasonable, and adequate. If there are objections, the Court will consider them, even if the objectors do not ask to speak at the hearing. The Court will listen to people who have asked to speak at the hearing. The Court may also decide the amount of attorneys' fees and expenses to award Lead Counsel and Lead Plaintiff. At or after the Settlement Hearing, the Court will decide whether to approve the Settlement and the Plan of Allocation. We do not know how long these decisions will take. You should be aware that the Court may change the date, time, and location of the Settlement Hearing without another notice being sent to Class Members.

There exists the possibility that the Court may decide to conduct the Settlement Hearing by video or telephonic conference, or otherwise allow Class Members to appear at the hearing by telephone or video conference, without further written notice to the Class. In order to determine whether the date and time of the Settlement Hearing have changed, or whether Class Members (who wish to attend the hearing) must or may participate by telephone or video, it is important that you monitor the Court's docket or the website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date and time of the hearing or updates regarding in-person or remote appearances at the hearing, will be posted to the Settlement website. Also, if the Court requires or allows Class Members to participate in the Settlement Hearing by telephone or video conference, the information for accessing the hearing will be posted to the Settlement website. Accordingly, please continue to check the Settlement website for important updates.

19. Do I have to come to the Settlement Hearing?

No. Lead Counsel will answer any questions the Court may have. But you are welcome to come at your own expense. If you are a Class Member and send an objection, you do not have to come to Court to talk about it. As long as you are a Class Member and mailed your complete written objection on time, the Court will consider it. You may also pay your own lawyer to attend the hearing, but it is not necessary. Class Members do not need to appear at the hearing or take any other action to indicate their approval.

20. May I speak at the Settlement Hearing?

If you object to the Settlement, the Plan of Allocation, and/or the fee and expense application, you may ask the Court for permission to speak at the Settlement Hearing. To do so, you must include with your objection (see question 16 above) a statement saying that it is your "Notice of Intention to Appear in the *Spectrum Pharmaceuticals Securities Settlement*." Persons who intend to object to the Settlement, the Plan of Allocation, and/or any attorneys' fees and expenses to be awarded to Lead Plaintiff's Counsel or Lead Plaintiff and desire to present evidence at the Settlement Hearing must include in their written objections the identity of any witnesses they may call to testify and any exhibits they intend to introduce into evidence at the Settlement Hearing. Your notice of intention to appear must be **received no later than September 29, 2025**, and addressed to the Clerk of Court, Lead Counsel, and Defendants' Counsel, at the addresses listed above in question 16.

You cannot speak at the hearing if you exclude yourself from the Class.

IF YOU DO NOTHING**21. What happens if I do nothing?**

If you do nothing, you will not receive any money from this Settlement. In addition, unless you exclude yourself from the Class, you will not be able to start a lawsuit, continue with a lawsuit, or be part of any other lawsuit against Defendants and the other Released Defendant Parties about the Released Plaintiff's Claims in this case.

GETTING MORE INFORMATION

22. How do I get more information?

For even more detailed information concerning the matters involved in this Litigation, you can obtain answers to common questions regarding the proposed Settlement by contacting the Claims Administrator toll-free at 1-833-586-3555 or by email at info@SpectrumPharmaceuticalsSecuritiesSettlement.com. Reference is also made to the Stipulation, to the pleadings in support of the Settlement, to the Orders entered by the Court and to the other settlement related papers filed in the Litigation, which are posted on the Settlement website at www.SpectrumPharmaceuticalsSecuritiesSettlement.com, and which may be inspected at the Office of the Clerk of the United States District Court for the District of Nevada, during regular business hours. For a fee, all papers filed in this Litigation are available at www.pacer.gov.

THE PROPOSED PLAN OF ALLOCATION OF NET SETTLEMENT FUND AMONG CLASS MEMBERS

23. How will my claim be calculated?

As discussed above, the Settlement provides \$15.95 million in cash for the benefit of the Class. The Settlement Amount and any interest it earns constitute the "Settlement Fund." The Settlement Fund, after deduction of Court-approved attorneys' fees and expenses, Notice and Administration Expenses, Taxes, and any other fees, expenses, or amounts approved by the Court, is the "Net Settlement Fund." If the Settlement is approved by the Court, the Net Settlement Fund will be distributed to eligible Authorized Claimants – *i.e.*, Members of the Class who timely submit valid Proofs of Claim that are accepted for payment by the Court – in accordance with this proposed Plan of Allocation ("Plan of Allocation" or "Plan") or such other plan of allocation as the Court may approve. Class Members who do not timely submit valid Proofs of Claim will not share in the Net Settlement Fund but will otherwise be bound by the Settlement. The Court may approve this proposed Plan of Allocation, or modify it, without additional notice to the Class. Any order modifying the Plan of Allocation will be posted on the Settlement website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

1. The objective of the Plan of Allocation is to equitably distribute the Net Settlement Fund among Members of the Class who submit acceptable Proofs of Claim ("Authorized Claimants") based on their respective alleged economic losses resulting from violations of the federal securities laws alleged in this Litigation. The Plan of Allocation reflects Lead Plaintiff's damages expert's analysis undertaken to that end, including a review of publicly available information regarding Spectrum and statistical analysis of the price movements of Spectrum common stock and the price performance of relevant market and peer indices during the Class Period. The Plan of Allocation, however, is not a formal damages analysis.

2. The calculations made pursuant to this Plan of Allocation are not intended to be estimates of, or indicative of, the amounts that Class Members might have been able to recover after a trial. Nor are the calculations pursuant to the Plan of Allocation intended to be estimates of the amounts that will be paid to Authorized Claimants pursuant to the Settlement. The computations under the Plan of Allocation are only a method to weigh the claims of Authorized Claimants against one another for the purposes of making equitable allocations of the Net Settlement Fund.

3. All purchases and acquisitions of Spectrum common stock during the Class Period (March 7, 2018 through August 5, 2021, both dates inclusive) are potentially eligible for compensation based on claims asserted under the Exchange Act.³

4. A "Recognized Loss Amount" will be calculated as set forth below for each purchase or acquisition of Spectrum common stock during the Class Period that is listed in the Proof of Claim and for which adequate documentation is provided. To the extent that the calculation of a Recognized Loss Amount results in a negative number, that number shall be set to zero.

5. As detailed below, the Net Settlement Fund will be allocated on a *pro rata* basis to Authorized Claimants.

³ Any transactions in Spectrum common stock executed outside of regular trading hours for the U.S. financial markets shall be deemed to have occurred during the next regular trading session.

I. Recognized Loss Amount Calculations on Spectrum Common Stock

6. In this case, Lead Plaintiff alleges that Defendants made false statements and omitted material facts during the Class Period, which had the effect of artificially inflating the trading price of Spectrum common stock. Lead Plaintiff further alleges that corrective information released to the market removed alleged artificial inflation (deflation) from the share prices of Spectrum common stock on December 20, 2018, December 26, 2019, December 23, 2020, and August 6, 2021 (the “corrective disclosures”).

7. Recognized Loss Amounts are based primarily on the difference in the amount of alleged artificial inflation in the prices of Spectrum common stock at the time of purchase and at the time of sale.⁴

8. For each share of exchange traded Spectrum common stock purchased or otherwise acquired from March 7, 2018, through and including August 5, 2021, and:

(a) Sold before December 20, 2018, the Recognized Loss Amount will be \$0.00.

(b) Sold from December 20, 2018, through and including the close of trading on August 5, 2021, the Recognized Loss Amount will be **the lesser of**: (i) the amount of artificial inflation per share on the date of purchase as stated in Table A below **minus** the amount of artificial inflation per share on the date of sale as stated in Table A below; or (ii) the purchase price **minus** the sale price, subject to clauses (e) and (f) below.

(c) Sold from August 6, 2021, through and including the close of trading on November 3, 2021, the Recognized Loss Amount will be **the least of**: (i) the amount of artificial inflation per share on the date of purchase as stated in Table A below; (ii) the purchase price **minus** the average closing price between August 6, 2021 and the date of sale as stated in Table B below; and (iii) the purchase price **minus** the sale price, subject to clauses (e) and (f) below.

(d) Held as of the close of trading on November 3, 2021, the Recognized Loss Amount will be **the lesser of**: (i) the amount of artificial inflation per share on the date of purchase as stated in Table A below; or (ii) the purchase price **minus** \$2.19, subject to clauses (e) and (f) below.⁵

(e) For each share of exchange traded Spectrum common stock purchased from March 7, 2018, through and including May 2, 2018, the Recognized Loss Amount calculated above shall be multiplied by 10%.

(f) For each share of exchange traded Spectrum common stock purchased from December 20, 2018, through and including December 22, 2020, the Recognized Loss Amount calculated above shall be multiplied by 50%.

⁴ Based on analyses by Lead Plaintiff’s damages expert, the following per share amounts of artificial inflation were dissipated by the corrective disclosures: \$3.70 on December 20, 2018, \$5.17 on December 26, 2019, \$0.43 on December 23, 2020, and \$0.60 on August 6, 2021. Lead Plaintiff’s damages expert discounted damages on purchases between March 7, 2018 and May 2, 2018 by 90%, discounted damages on purchases between December 20, 2018 and December 22, 2020 by 50%, and discounted the final corrective disclosure and related artificial inflation estimate by 90%, to account for the significant litigation risk and low probability of recovering damages in light of the Court’s October 7, 2024 Order on Defendants’ motion to dismiss. As a result, Table A below reflects \$0.06 of artificial inflation dissipated upon the final corrective disclosure.

⁵ Pursuant to Section 21D(e)(1) of the Exchange Act, “in any private action arising under this title in which the plaintiff seeks to establish damages by reference to the market price of a security, the award of damages to the plaintiff shall not exceed the difference between the purchase or sale price paid or received, as appropriate, by the plaintiff for the subject security and the mean trading price of that security during the 90-day period beginning on the date on which the information correcting the misstatement or omission that is the basis for the action is disseminated to the market.” Consistent with the requirements of the Exchange Act, Recognized Loss Amounts are reduced to an appropriate extent by taking into account the closing prices of Spectrum common stock during the “90-day look-back period,” August 6, 2021, through and including November 3, 2021. The mean (average) closing price for Spectrum common stock during this 90-day look-back period was \$2.19.

ADDITIONAL PROVISIONS

9. **Calculation of Claimant's "Recognized Claim":** A claimant's "Recognized Claim" will be the sum of his, her, or its Recognized Loss Amounts as calculated above with respect to Spectrum common stock. If a claimant had a market gain with respect to their overall transactions in Spectrum common stock during the Class Period, the value of the claimant's Recognized Claim will be zero. If a claimant suffered an overall market loss with respect to their overall transactions in Spectrum common stock during the Class Period, but that market loss was less than the claimant's total Recognized Claim, their Recognized Claim will be limited to the amount of the actual market loss. For purposes of determining whether a claimant had a market gain, or suffered a market loss, with respect to a claimant's overall transactions of Spectrum common stock during the Class Period, the Claims Administrator will determine the difference between, the claimant's (i) Total Purchase Amount⁶ and (ii) the sum of the Total Sales Proceeds⁷ and Holding Value.⁸

10. **FIFO Matching:** If a Class Member made more than one purchase, acquisition, or sale of Spectrum common stock during the Class Period, all purchases, acquisitions, and sales will be matched on a First In, First Out ("FIFO") basis, beginning with the earliest purchase of the security.

11. **"Purchase/Sale" Prices:** For the purposes of calculations under this Plan of Allocation, "purchase price" means the actual price paid, excluding all fees, taxes, and commissions, and "sale price" means the actual amount received, not deducting any fees, taxes, and commissions.

12. **"Purchase/Sale" Dates:** Purchases, acquisitions, and sales of Spectrum common stock will be deemed to have occurred on the "contract" or "trade" date as opposed to the "settlement" or "payment" date. The receipt or grant by gift, inheritance, or operation of law of Spectrum common stock shall not be deemed a purchase, acquisition, or sale of Spectrum common stock for the calculation of a claimant's Recognized Loss Amount, nor shall the receipt or grant be deemed an assignment of any claim relating to the purchase, acquisition, or sale of Spectrum common stock unless: (i) the donor or decedent purchased, acquired, or sold those shares of Spectrum common stock between March 7, 2018, and November 3, 2021 (both dates inclusive); (ii) the instrument of gift or assignment specifically provides that it is intended to transfer such rights; and (iii) no other duplicative Claim was submitted by or on behalf of the donor, on behalf of the decedent, or by anyone else with respect to such shares of Spectrum common stock.

13. **Short Sales:** In accordance with the Plan of Allocation, the Recognized Loss Amount on any portion of a transaction that matches against (or "covers") a "short sale" is zero. The Recognized Loss Amount on a "short sale" that is not covered is also zero.

14. In the event that a claimant establishes a short position during the Class Period, the earliest subsequent Class Period purchase shall be matched against such short position on a FIFO basis and will not be entitled to a recovery.

⁶ The "Total Purchase Amount" is the total amount the claimant paid (excluding commissions and other charges) for Spectrum common stock purchased during the Class Period.

⁷ The Claims Administrator will match any sales of Spectrum common stock from the start of the Class Period through and including the close of trading on November 3, 2021, first against the claimant's opening position (the proceeds of those sales will not be considered for purposes of calculating market gains or losses). The total amount received (excluding commissions and other charges) for the remaining sales of Spectrum common stock sold from the start of the Class Period through and including the close of trading on November 3, 2021 will be the "Total Sales Proceeds."

⁸ The Claims Administrator will ascribe a "Holding Value" for the securities equal to \$2.22 (the closing price of Spectrum common stock on November 3, 2021) for each share of Spectrum common stock purchased during the Class Period and still held as of the close of trading on November 3, 2021.

15. **Common Stock Purchased/Sold Through the Exercise of Options:** With respect to Spectrum common stock purchased or sold via the exercise of an option, the purchase/sale date of the Spectrum common stock is the exercise date of the option and the purchase/sale price is the exercise price of the option.

16. **Determination of Distribution Amount:** If the sum total of Recognized Claims of all Authorized Claimants who are entitled to receive payment out of the Net Settlement Fund is greater than the Net Settlement Fund, each Authorized Claimant shall receive the claimants' authorized share of the Net Settlement Fund as provided by this Plan of Allocation. That share will be the Authorized Claimant's Recognized Claim divided by the total of Recognized Claims of all Authorized Claimants, multiplied by the total amount of the Net Settlement Fund.

17. If an Authorized Claimant's *pro rata* share of the Net Settlement Fund calculates to less than \$10.00, no distribution will be made to that Authorized Claimant.

18. Payment pursuant to the Plan of Allocation or such other plan as may be approved by the Court for this Settlement shall be conclusive against all Authorized Claimants. No person shall have any claim against Lead Plaintiff, Lead Plaintiff's Counsel, Lead Plaintiff's damages expert, Defendants, Defendants' Counsel, any of the other Class Members, the Claims Administrator, or other agent designated by Lead Plaintiff's Counsel arising from distributions made substantially in accordance with the Stipulation, the plan of allocation approved by the Court, or further orders of the Court.

19. Class Members who do not submit acceptable Proofs of Claim will not share in the distribution of the Net Settlement Fund; however, they will nevertheless be bound by the Settlement and the Order and Final Judgment of the Court dismissing this Litigation unless they have timely and validly sought exclusion.

20. The Court has reserved jurisdiction to allow, disallow, or adjust on equitable grounds the claim of any Class Member or claimant.

21. Each claimant shall be deemed to have submitted to the jurisdiction of the Court with respect to the claimant's Claim and Proof of Claim.

TABLE A
Estimated Inflation in Spectrum Common Stock
March 7, 2018 through August 5, 2021

Date Range	Inflation Per Share of Spectrum Common Stock
March 7, 2018 – December 19, 2018	\$9.36
December 20, 2018 – December 25, 2019	\$5.66
December 26, 2019 – December 22, 2020	\$0.49
December 23, 2020 – August 5, 2021	\$0.06

TABLE B
90-Day Look-back Table for Spectrum Common Stock
Closing Price and Average Closing Price
August 6, 2021 through November 3, 2021

Date	Closing Price	Average Closing Price Between August 6, 2021 and Date Shown		Date	Closing Price	Average Closing Price Between August 6, 2021 and Date Shown
8/6/2021	\$2.55	\$2.55		9/22/2021	\$2.31	\$2.32
8/9/2021	\$2.57	\$2.56		9/23/2021	\$2.40	\$2.32
8/10/2021	\$2.39	\$2.50		9/24/2021	\$2.37	\$2.32
8/11/2021	\$2.35	\$2.47		9/27/2021	\$2.42	\$2.33
8/12/2021	\$2.35	\$2.44		9/28/2021	\$2.32	\$2.33
8/13/2021	\$2.26	\$2.41		9/29/2021	\$2.23	\$2.32
8/16/2021	\$2.27	\$2.39		9/30/2021	\$2.18	\$2.32
8/17/2021	\$2.33	\$2.38		10/1/2021	\$2.20	\$2.32
8/18/2021	\$2.21	\$2.36		10/4/2021	\$2.06	\$2.31
8/19/2021	\$2.18	\$2.35		10/5/2021	\$2.01	\$2.30
8/20/2021	\$2.27	\$2.34		10/6/2021	\$1.95	\$2.29
8/23/2021	\$2.34	\$2.34		10/7/2021	\$2.00	\$2.29
8/24/2021	\$2.38	\$2.34		10/8/2021	\$1.97	\$2.28
8/25/2021	\$2.43	\$2.35		10/11/2021	\$1.99	\$2.27
8/26/2021	\$2.35	\$2.35		10/12/2021	\$1.94	\$2.27
8/27/2021	\$2.38	\$2.35		10/13/2021	\$1.97	\$2.26
8/30/2021	\$2.30	\$2.35		10/14/2021	\$2.02	\$2.26
8/31/2021	\$2.35	\$2.35		10/15/2021	\$1.96	\$2.25
9/1/2021	\$2.40	\$2.35		10/18/2021	\$2.00	\$2.25
9/2/2021	\$2.39	\$2.35		10/19/2021	\$2.05	\$2.24
9/3/2021	\$2.28	\$2.35		10/20/2021	\$1.96	\$2.24
9/7/2021	\$2.21	\$2.34		10/21/2021	\$1.99	\$2.23
9/8/2021	\$2.19	\$2.34		10/22/2021	\$1.99	\$2.23
9/9/2021	\$2.20	\$2.33		10/25/2021	\$1.96	\$2.22
9/10/2021	\$2.21	\$2.33		10/26/2021	\$1.89	\$2.22
9/13/2021	\$2.24	\$2.32		10/27/2021	\$1.80	\$2.21
9/14/2021	\$2.15	\$2.32		10/28/2021	\$1.94	\$2.21
9/15/2021	\$2.27	\$2.31		10/29/2021	\$1.83	\$2.20
9/16/2021	\$2.33	\$2.31		11/1/2021	\$1.93	\$2.19
9/17/2021	\$2.43	\$2.32		11/2/2021	\$2.06	\$2.19
9/20/2021	\$2.32	\$2.32		11/3/2021	\$2.22	\$2.19
9/21/2021	\$2.34	\$2.32				

SPECIAL NOTICE TO SECURITIES BROKERS AND OTHER NOMINEES

Nominees who purchased or acquired Spectrum common stock during the Class Period for beneficial owners who are Class Members are directed to: (i) request within seven (7) calendar days of receipt of the Postcard Notice sufficient copies of the Postcard Notice from the Claims Administrator to forward to all such beneficial owners; or (ii) send a list of the names and addresses (including email addresses if available) of such beneficial owners to the Claims Administrator, at notifications@veritaglobal.com or the address below, within seven (7) calendar days after receipt of the Postcard Notice. If a nominee elects to send the Postcard Notice to beneficial owners, such nominee is directed to email or mail (where an email is unavailable) the Postcard Notice within seven (7) calendar days of receipt of those documents from the Claims Administrator, and upon such emailing or mailing, the nominee shall send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed, and the nominee shall retain the list of names and addresses for use in connection with any possible future notice to the Class. Upon full compliance with these instructions, including the timely emailing or mailing of the Postcard Notice to beneficial owners, such nominees may seek reimbursement of their reasonable expenses actually incurred in complying with these instructions by providing the Claims Administrator with proper documentation supporting the expenses for which reimbursement is sought and reflecting compliance with these instructions. Reasonable out-of-pocket expenses actually incurred in connection with the foregoing includes up to \$0.03 per record for providing names, addresses, and email addresses to the Claims Administrator; up to a maximum of \$0.03 per Postcard Notice mailed by you, plus postage at the rate used by the Claims Administrator; or \$0.03 per Postcard Notice sent by email. Such properly documented expenses incurred by nominees in compliance with the terms of these instructions will be paid from the Settlement Fund.

Spectrum Pharmaceuticals Securities Settlement
Claims Administrator
c/o Verita Global
P.O. Box 301171
Los Angeles, CA 90030-1171

DATED: June 16, 2025

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

JOSE CHUNG LUO, Individually and on Behalf of)	No. 2:21-cv-01612-CDS-BNW
All Others Similarly Situated,)	<u>CLASS ACTION</u>
Plaintiff,)	
vs.)	PROOF OF CLAIM AND RELEASE
SPECTRUM PHARMACEUTICALS, INC., et al.,)	
Defendants.)	
_____)	

I. GENERAL INSTRUCTIONS

1. To recover as a Class Member based on the claims in the Litigation,¹ you must complete and, on page 9 hereof, sign this Proof of Claim. If you fail to submit a properly addressed (as set forth in paragraph 3 below) Proof of Claim, your claim may be rejected and you may be precluded from any recovery from the Net Settlement Fund created in connection with the proposed Settlement.

2. Submission of this Proof of Claim, however, does not assure that you will share in the proceeds of the Settlement of the Litigation.

3. **YOU MUST MAIL OR SUBMIT ONLINE YOUR COMPLETED AND SIGNED PROOF OF CLAIM, ACCOMPANIED BY COPIES OF THE DOCUMENTS REQUESTED HEREIN, ON OR BEFORE OCTOBER 1, 2025, ADDRESSED AS FOLLOWS:**

Spectrum Pharmaceuticals Securities Settlement
Claims Administrator
c/o Verita Global
P.O. Box 301171
Los Angeles, CA 90030-1171

Online Submissions: www.SpectrumPharmaceuticalsSecuritiesSettlement.com

If you are NOT a Class Member, as defined in the Notice of Pendency and Proposed Settlement of Class Action ("Notice"), DO NOT submit a Proof of Claim.

4. If you are a Class Member and you do not timely request exclusion from the Class, you will be bound by the terms of any judgment entered in the Litigation, including the Releases provided therein, **WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM.**

5. If you are a Class Member, you will be bound by the terms of any judgments or orders entered in the Litigation **WHETHER OR NOT YOU SUBMIT A PROOF OF CLAIM**, unless you submit a request for exclusion from the Class. Thus, if you are a Class Member, the Judgment will release the Released Defendant Parties from all Released Plaintiff's Claims, and you will be forever barred and enjoined from commencing, instituting, prosecuting, or continuing to prosecute any action or other proceeding in any court of law or equity, arbitration tribunal, or administrative forum asserting any of the Released Plaintiff's Claims against any of the Released Defendant Parties.

6. You are eligible to participate in the distribution of the Net Settlement Fund only if you are a Member of the Class and if you complete and return this form as specified below. If you fail to submit a timely, properly addressed, and completed Proof of Claim with the required documentation, your claim may be rejected and you may be precluded from receiving any distribution from the Net Settlement Fund.

7. Submission of this Proof of Claim does not guarantee that you will share in the proceeds of the Settlement. The distribution of the Net Settlement Fund will be governed by the Plan of Allocation set forth in the Notice, if it is approved by the Court, or by such other plan of allocation approved by the Court.

¹ This Proof of Claim and Release form ("Proof of Claim") incorporates by reference the definitions in the Stipulation of Settlement dated May 9, 2025 ("Stipulation"), which can be obtained at www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

II. CLAIMANT IDENTIFICATION

You are a Member of the Class if you purchased or otherwise acquired the common stock of Spectrum Pharmaceuticals, Inc. ("Spectrum") between March 7, 2018, and August 5, 2021, inclusive (the "Class Period"), and are not otherwise excluded from the Class.

Use Part I of this form entitled "Claimant Identification" to identify each purchaser or acquirer of record ("nominee") of the Spectrum common stock that forms the basis of this claim. **THIS PROOF OF CLAIM MUST BE FILED BY THE ACTUAL BENEFICIAL PURCHASER(S) OR ACQUIRER(S) OR THE LEGAL REPRESENTATIVE OF SUCH PURCHASER(S) OR ACQUIRER(S) OF SPECTRUM COMMON STOCK UPON WHICH THIS CLAIM IS BASED.**

All joint purchasers or acquirers must sign this Proof of Claim. If you purchased or otherwise acquired Spectrum common stock during the Class Period and held the securities in your name, you are the beneficial owner as well as the record owner and you must sign this Proof of Claim to participate in the Settlement. If, however, you purchased or otherwise acquired Spectrum common stock during the Class Period and the shares were registered in the name of a third party, such as a nominee or brokerage firm, you are the beneficial owner of these shares, but the third party is the record owner. The beneficial owner, not the record owner, must sign this Proof of Claim.

Executors, administrators, guardians, conservators, and trustees must complete and sign this Proof of Claim on behalf of Persons represented by them and their authority must accompany this claim and their titles or capacities must be stated. Specifically, they must: (i) expressly state the capacity in which they are acting; (ii) identify the name, account number, last four digits of the Social Security Number (or full taxpayer identification number), address, and telephone number of the beneficial owner of (or other Person or entity on whose behalf they are acting with respect to) the Spectrum common stock; and (iii) furnish herewith evidence of their authority to bind to the Proof of Claim the Person or entity on whose behalf they are acting. (Authority to complete and sign a Proof of Claim cannot be established by stockbrokers demonstrating only that they have discretionary authority to trade stock in another Person's accounts.)

The last four digits of the Social Security Number (or full Taxpayer Identification Number) and telephone number of the beneficial owner may be used in verifying the claim. Failure to provide the foregoing information could delay verification of your claim or result in the rejection of the claim.

You are required to submit genuine and sufficient documentation for all of your transactions and holdings in the Spectrum common stock set forth in the "Schedule of Transactions" in Part II of this Proof of Claim. Documentation may consist of copies of brokerage confirmation slips or monthly brokerage account statements, or an authorized statement from your broker containing the transactional and holding information found in a broker confirmation slip or account statement. The Settling Parties and the Claims Administrator do not independently have information about your investments in Spectrum common stock. **IF SUCH DOCUMENTS ARE NOT IN YOUR POSSESSION, PLEASE OBTAIN COPIES OR EQUIVALENT CONTEMPORANEOUS DOCUMENTS FROM YOUR BROKER. FAILURE TO SUPPLY THIS DOCUMENTATION MAY RESULT IN THE REJECTION OF YOUR CLAIM. DO NOT SEND ORIGINAL DOCUMENTS.** Please keep a copy of all documents that you send to the Claims Administrator. Also, please do not highlight any portion of the Proof of Claim or any supporting documents.

A Proof of Claim should be submitted for each separate legal entity (e.g., a claim of joint owners should not include separate transactions of just one of the joint owners, and an individual should not combine his or her IRA transactions with transactions made solely in the individual's name). Conversely, a single Proof of Claim should be submitted on behalf of one legal entity including all transactions made by that entity, no matter how many separate accounts that entity has (e.g., an institution with multiple brokerage accounts that the entity has transacted in Spectrum common stock during the Class Period).

By submitting a signed Proof of Claim, you will be swearing that you: (i) own(ed) the Spectrum common stock you have listed in the Proof of Claim; or (ii) are expressly authorized to act on behalf of the owner thereof.

By submitting a signed Proof of Claim, you will be swearing to the truth of the statements contained therein and the genuineness of the documents attached thereto, subject to penalties of perjury under the laws of the United States of America. The making of false statements, or the submission of forged or fraudulent documentation, will result in the rejection of your claim and may subject you to civil liability or criminal prosecution.

If the Court approves the Settlement, payments to eligible Authorized Claimants pursuant to the Plan of Allocation (or such other plan of allocation as the Court approves) will be made after the completion of all claims processing. This could take substantial time. Please be patient.

If you have questions concerning the Proof of Claim, or need additional copies of the Proof of Claim or the Notice, you may contact the Claims Administrator, *Spectrum Pharmaceuticals Securities Settlement*, Claims Administrator, c/o Verita Global at P.O. Box 301171, Los Angeles, CA 90030-1171, or by email at info@SpectrumPharmaceuticalsSecuritiesSettlement.com, or by toll-free phone at 1-833-586-3555, or you may download the documents from the Settlement website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

III. CLAIM FORM

Use Part II of this form entitled "Schedule of Transactions in Spectrum Common Stock" to supply all required details of your transaction(s). If you need more space or additional schedules, attach separate sheets giving all of the required information in substantially the same form. Sign and print or type your name on each additional sheet.

On the schedules, provide all of the requested information with respect to ***all*** of your purchases, acquisitions, and sales of Spectrum common stock that took place between March 7, 2018 and November 3, 2021, inclusive, whether such transactions resulted in a profit or a loss.² You must also provide all of the requested information with respect to the number of shares of Spectrum common stock you held at the close of trading on March 6, 2018, August 5, 2021, and November 3, 2021. Failure to report all such transactions may result in the rejection of your claim.

List each transaction separately and in chronological order, by trade date, beginning with the earliest. You must accurately provide the month, day, and year of each transaction you list.

The date of covering a "short sale" is deemed to be the date of purchase or other acquisition of Spectrum common stock. The date of a "short sale" is deemed to be the date of sale of Spectrum common stock.

² Information requested about your purchases/acquisitions on August 6, 2021 through and including the close of trading on November 3, 2021 is needed only for the Claims Administrator to confirm that you have reported all relevant transactions. Purchases/acquisitions during this period are not eligible for a recovery because they are outside the Class Period.

COPIES OF BROKER CONFIRMATIONS OR OTHER DOCUMENTATION OF YOUR TRANSACTIONS IN SPECTRUM COMMON STOCK SHOULD BE ATTACHED TO YOUR PROOF OF CLAIM. FAILURE TO PROVIDE THIS DOCUMENTATION COULD DELAY VERIFICATION OF YOUR CLAIM OR RESULT IN THE REJECTION OF YOUR CLAIM. **THE PARTIES DO NOT HAVE INFORMATION ABOUT YOUR TRANSACTIONS IN SPECTRUM COMMON STOCK.**

PLEASE NOTE: As set forth in the Plan of Allocation contained in the Notice, each Authorized Claimant shall receive his, her, its, or their *pro rata* share of the Net Settlement Fund. If the prorated payment to any Authorized Claimant calculates to less than \$10.00, it will not be included in the calculation and no distribution will be made to that Authorized Claimant.

NOTICE REGARDING ELECTRONIC FILES: Certain claimants with large numbers of transactions may request, or may be requested, to submit information regarding their transactions in electronic files. This is different from the online submission process that is available at www.SpectrumPharmaceuticalsSecuritiesSettlement.com. All claimants MUST submit a manually signed paper Proof of Claim whether or not they also submit electronic copies. If you have a large number of transactions and wish to file your claim electronically, you must contact the Claims Administrator at edata@veritaglobal.com to obtain the required file layout. Any file not in accordance with the required electronic filing format will be subject to rejection. Only one claim should be submitted for each separate legal entity, and the complete name of the beneficial owner(s) of the securities must be entered where called for. Distribution payments must be made by check or electronic payment payable to the Authorized Claimant (beneficial account owner). The third-party filer shall not be the payee of any distribution payment or electronic distribution payment. No electronic files will be considered to have been properly submitted unless the Claims Administrator issues to the claimant a written acknowledgment of receipt and acceptance of electronically submitted data.

Official
Office
Use
Only

UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

Luo v. Spectrum Pharmaceuticals, Inc., et al.

No. 2:21-cv-01612-CDS-BNW

PROOF OF CLAIM AND RELEASE

**Must Be Postmarked (if Mailed)
or Received (if Submitted Online)
No Later Than October 1, 2025**

SPPS

Please Type or Print in the Boxes Below

Must use Black or Blue Ink or your
claim may be deemed deficient.

REMEMBER TO ATTACH COPIES OF BROKER CONFIRMATIONS OR OTHER DOCUMENTATION OF YOUR TRANSACTIONS IN SPECTRUM COMMON STOCK. FAILURE TO PROVIDE THIS DOCUMENTATION COULD DELAY VERIFICATION OF YOUR CLAIM OR RESULT IN THE REJECTION OF YOUR CLAIM.

PART I. CLAIMANT IDENTIFICATION

Last Name

M.I.

First Name

Last Name (Co-Beneficial Owner)

M.I.

First Name (Co-Beneficial Owner)

☐ IRA

☐ Joint Tenancy

☐ Employee

☐ Individual

☐ Other

Company Name (Beneficial Owner - If Claimant is not an Individual) or Custodian Name if an IRA (specify)

Trustee/Asset Manager/Nominee/Record Owner's Name (If Different from Beneficial Owner Listed Above)

Account#/Fund# (Not Necessary for Individual Filers)

Social Security Number (Last 4 digits)

Taxpayer Identification Number

or

Telephone Number (Primary Daytime)

Telephone Number (Alternate)

Email Address

MAILING INFORMATION

Address

Address (cont.)

City

State

ZIP Code

Foreign Province

Foreign Postal Code

Foreign Country Name/Abbreviation

FOR CLAIMS
PROCESSING
ONLY

OB

CB

☐ ATP
☐ KE
☐ ICI

☐ BE
☐ DR
☐ EM

☐ FL
☐ ME
☐ ND

☐ OP
☐ RE
☐ SH

MM / DD / YYYY

FOR CLAIMS
PROCESSING
ONLY



PART II: SCHEDULE OF TRANSACTIONS IN SPECTRUM COMMON STOCK

☐ Y ☐ N

B. Purchases or other acquisitions of Spectrum common stock between March 7, 2018 and November 3, 2021, inclusive:

PURCHASES

PURCHASES																															
	Trade Date(s) (List Chronologically)								Number of Shares Purchased or Acquired							Total Purchase or Acquisition Price (Excluding commissions, taxes, and fees)				Proof of Purchase/ Acquisition Enclosed											
	M	M	/	D	D	/	Y	Y	Y	Y									\$												
1.			/			/													\$											<input type="radio"/> Y	<input type="radio"/> N
2.			/			/													\$											<input type="radio"/> Y	<input type="radio"/> N
3.			/			/													\$											<input type="radio"/> Y	<input type="radio"/> N
4.			/			/													\$											<input type="radio"/> Y	<input type="radio"/> N
5.			/			/													\$											<input type="radio"/> Y	<input type="radio"/> N

IMPORTANT: (i) If any purchase listed covered a “short sale,” please mark Yes: ☒ Yes

(ii) If you received shares through an acquisition or merger, please identify the date, the share amount and the company acquired:

M	M		D	D		Y	Y	Y	Y		Merger Shares:									Company:					
<input type="text"/>	<input type="text"/>	/	<input type="text"/>	<input type="text"/>	/	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>		<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>							

C. Sales of Spectrum common stock between March 7, 2018 and November 3, 2021, inclusive:

SALES

SALES																													
	Trade Date(s) (List Chronologically)								Number of Shares Sold						Total Sales Price (Excluding commissions, taxes and fees)				Proof of Sale Enclosed?										
	M	M	/	D	D	/	Y	Y	Y	Y							\$												
1.			/			/											\$.00	<input type="radio"/> Y	<input type="radio"/> N
2.			/			/											\$.00	<input type="radio"/> Y	<input type="radio"/> N
3.			/			/											\$.00	<input type="radio"/> Y	<input type="radio"/> N
4.			/			/											\$.00	<input type="radio"/> Y	<input type="radio"/> N
5.			/			/											\$.00	<input type="radio"/> Y	<input type="radio"/> N

☐ Y ☐ N

☐ Y ☐ N

If you require additional space, attach extra schedules in the same format as above. Sign and print your name and the last four digits of your Social Security/Taxpayer Identification Number on each additional page.

YOU MUST READ THE RELEASE AND SIGN THE CERTIFICATION ON PAGE 9. FAILURE TO SIGN THE CERTIFICATION MAY RESULT IN A DELAY IN PROCESSING OR THE REJECTION OF YOUR CLAIM.



IV. SUBMISSION TO JURISDICTION OF COURT AND ACKNOWLEDGMENTS

I (We) submit this Proof of Claim under the terms of the Stipulation described in the Notice. I (We) also submit to the jurisdiction of the United States District Court for the District of Nevada with respect to my (our) claim as a Class Member and for purposes of enforcing the release set forth herein. I (We) further acknowledge that I am (we are) bound by and subject to the terms of any judgment that may be entered in the Litigation. I (We) agree to furnish additional information to the Claims Administrator to support this claim if requested to do so. I (We) have not submitted any other claim covering the same purchases, other acquisitions, or sales of Spectrum common stock during the relevant period and know of no other Person having done so on my (our) behalf.

V. RELEASE

1. I (We) hereby acknowledge full and complete satisfaction of, and do hereby fully, finally, and forever waive, release, relinquish, discharge, and dismiss from the Released Plaintiff's Claims each and all of the "Released Defendant Parties," defined as any or all of Defendants and/or any or all of their current, former, or future parents, affiliates, subsidiaries, business units, divisions, or controlling shareholders; and each and all of their and Defendants' respective current, former, or future officers, directors, employees, members, managers, partners, principals, controlling shareholders, agents, advisors, accountants, auditors, insurers, reinsurers, and attorneys; and the predecessors, successors, estates, assigns, assignees, immediate family members, spouses, heirs, executors, trusts, trustees, administrators, agents, legal or personal representatives of each of them, in their capacities as such.

2. "Released Plaintiff's Claims" means all claims and causes of action of every nature and description, whether known or unknown, including Unknown Claims (as defined below), whether arising under federal, state, local, common, statutory, administrative or foreign law, or any other law, rule or regulation, at law or inequity, whether class or individual in nature, whether accrued or unaccrued, whether liquidated or unliquidated, whether matured or unmatured, that Lead Plaintiff or any other Class Member has or could have asserted in any court or forum, based on, arising out of, or in connection with: (i) any purchase or acquisition of Spectrum common stock during the period between March 7, 2018, and August 5, 2021, inclusive; and (ii) the allegations, acts, facts, matters, occurrences, transactions, disclosures, filings, representations, statements, or omissions that were or could have been alleged by Lead Plaintiff or any other Member of the Class in the Litigation. Released Plaintiff's Claims do not include: (i) any claims related to the enforcement of the Settlement; (ii) any claims asserted in the actions styled: (a) *Christiansen v. Spectrum Pharmaceuticals, Inc.*, Case No. 1:22-cv-10292-VEC (S.D.N.Y.); (b) *Ayoub v. Spectrum Pharmaceuticals, Inc.*, Case No. 1:24-cv-8138-VEC (S.D.N.Y.); (c) *Changyoung Jung, derivatively on behalf of Spectrum Pharmaceuticals, Inc. and Assertio Holdings, Inc. v. Francois Lebel, et al.*, Case No. 2024-0821 (Del. Ch.); or (d) *Changyoung Jung, derivatively on behalf of Spectrum Pharmaceuticals, Inc. and Assertio Holdings, Inc. v. Joseph Turgeon, et al.*, Case No. 2024-0822 (Del. Ch.); (iii) any claims arising out of ERISA; or (iv) any claims of any Person who or which submits a request for exclusion from the Class that is accepted by the Court.

3. "Unknown Claims" means: (a) any and all Released Plaintiff's Claims that any of the Releasing Plaintiff Parties do not know or suspect to exist in his, her, or its favor at the time of the release of such claims; and (b) any and all Released Defendants' Claims that any of the Released Defendant Parties do not know or suspect to exist in his, her, or its favor at the time of the release of such claims, which, if known by him, her, or it, might have affected his, her, or its decision(s) with respect to this Settlement. With respect to: (a) any and all Released Plaintiff's Claims against the Released Defendant Parties; and (b) any and all Released Defendants' Claims against the Releasing Plaintiff Parties, the Settling Parties stipulate and agree that, upon the Effective Date, the Settling Parties shall expressly waive, and each Releasing Plaintiff Party and Released Defendant Party shall be deemed to have, and by operation of the Judgment shall have expressly waived, any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States, or principle of common law or foreign law, that is similar, comparable, or equivalent to California Civil Code §1542, which provides:

A general release does not extend to claims that the creditor or releasing party does not know or suspect to exist in his or her favor at the time of executing the release and that, if known by him or her, would have materially affected his or her settlement with the debtor or released party.

The Settling Parties shall fully, finally, and forever expressly waive any and all provisions, rights, and benefits conferred by any law of any state or territory of the United States or any other jurisdiction, or principle of common law, which is similar, comparable, or equivalent to California Civil Code §1542. The Releasing Plaintiff Parties and Released Defendant Parties acknowledge that they may hereafter discover facts, legal theories, or authorities in addition to or different from those which he, she, it, or their counsel now knows or believes to be true with respect to the subject matter of the Released Plaintiff's Claims or Released Defendants' Claims, but: (a) the Releasing Plaintiff Parties shall expressly, fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Releasing Plaintiff Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Plaintiff's Claims against the Released Defendant Parties, known or unknown, suspected or unsuspected, contingent or non-contingent, accrued or unaccrued, whether or not concealed or hidden, which now



exist, or heretofore have existed, or may hereafter exist, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law, or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities; and (b) the Released Defendant Parties shall expressly, fully, finally, and forever waive, compromise, settle, discharge, extinguish, and release, and each Released Defendant Party shall be deemed to have waived, compromised, settled, discharged, extinguished, and released, and upon the Effective Date, and by operation of the Judgment shall have waived, compromised, settled, discharged, extinguished, and released, fully, finally, and forever, any and all Released Defendants' Claims against Lead Plaintiff, the Class, and Lead Plaintiff's Counsel, known or unknown, suspected or unsuspected, contingent or non-contingent, whether or not concealed or hidden, which now exist, or heretofore have existed, upon any theory of law or equity now existing or coming into existence in the future, including, but not limited to, conduct which is negligent, intentional, with or without malice, or a breach of any duty, law or rule, without regard to the subsequent discovery or existence of such different or additional facts, legal theories, or authorities. The Settling Parties acknowledge, and the Releasing Plaintiff Parties and Released Defendant Parties shall be deemed by operation of law to have acknowledged, that the foregoing waiver was separately bargained for and is a key element of the Settlement of which this release is a part.

4. These Releases shall be of no force or effect unless and until the Court approves the Stipulation and the Settlement becomes effective on the Effective Date.

CERTIFICATION

By signing and submitting this Proof of Claim, the claimant(s) or the Person(s) who represent(s) the claimant(s) certifies (certify), as follows:

1. that I (we) read and understand the contents of the Notice and this Proof of Claim, including the Releases provided for in the Settlement and the terms of the Plan of Allocation;
2. that the claimant(s) is a (are) Class Member(s), as defined in the Notice and on page 2 of this Proof of Claim, and is (are) not excluded from the Class by definition or pursuant to request as set forth in the Notice;
3. that I (we) own(ed) the Spectrum common stock identified in the Proof of Claim and have not assigned the claim against the Released Defendant Parties to another, or that, in signing and submitting this Proof of Claim, I (we) have the authority to act on behalf of the owner(s) thereof;
4. that the claimant(s) has (have) not submitted any other claim covering the same purchases/acquisitions of Spectrum common stock, and knows (know) of no other Person having done so on the claimant's (claimants') behalf;
5. that the claimant(s) submit(s) to the jurisdiction of the Court with respect to claimant's (claimants') claim and for purposes of enforcing the Releases set forth herein;
6. that I (we) agree to furnish such additional information with respect to this Proof of Claim as Lead Counsel, the Claims Administrator, or the Court may require;
7. that the claimant(s) waive(s) the right to trial by jury, to the extent it exists, and agree(s) to the Court's summary disposition of the determination of the validity and amount of the claim made by means of this Proof of Claim;
8. that I (we) acknowledge that the claimant(s) will be bound by and subject to the terms of any judgment(s) that may be entered in the Litigation; and
9. that the claimant(s) is (are) NOT subject to backup withholding under the provisions of Section 3406(a)(1)(C) of the Internal Revenue Code because: (i) the claimant(s) is (are) exempt from backup withholding; or (ii) the claimant(s) has (have) not been notified by the IRS that he/she/it is subject to backup withholding as a result of a failure to report all interest or dividends; or (iii) the IRS has notified the claimant(s) that he/she/it is no longer subject to backup withholding. If the IRS has notified the claimant(s) that he, she, or it is subject to backup withholding, please strike out the language in the preceding sentence indicating that the claim is not subject to backup withholding in the certification above.



UNDER THE PENALTIES OF PERJURY, I (WE) CERTIFY THAT ALL OF THE INFORMATION PROVIDED BY ME (US) ON THIS PROOF OF CLAIM IS TRUE, CORRECT, AND COMPLETE, AND THAT THE DOCUMENTS SUBMITTED HERewith ARE TRUE AND CORRECT COPIES OF WHAT THEY PURPORT TO BE:

Executed this _____ day of _____ in _____
(Month/Year) (City/State/Country)

(Sign your name here)

(Sign your name here)

(Type or print your name here)

(Type or print your name here)

(Capacity of person(s) signing, e.g.,
Beneficial Purchaser or Acquirer, Executor or Administrator)

(Capacity of person(s) signing, e.g.,
Beneficial Purchaser or Acquirer, Executor or Administrator)

**ACCURATE CLAIMS PROCESSING TAKES A SIGNIFICANT AMOUNT OF TIME.
THANK YOU FOR YOUR PATIENCE.**

Reminder Checklist:

1. Please sign the above release and acknowledgment.
2. Remember to attach copies of supporting documentation.
3. **Do not send** originals of certificates or other documentation as they will not be returned.
4. Keep a copy of your Proof of Claim and all supporting documentation for your records.
5. If you desire an acknowledgment of receipt of your Proof of Claim, please send it Certified Mail, Return Receipt Requested.
6. If you move, please send your new address to the address below.
7. **Do not use red pen or highlighter** on the Proof of Claim or supporting documentation.

**THIS PROOF OF CLAIM MUST BE SUBMITTED ONLINE OR MAILED
NO LATER THAN OCTOBER 1, 2025, ADDRESSED AS FOLLOWS:**

Spectrum Pharmaceuticals Securities Settlement

Claims Administrator

c/o Verita Global

P.O. Box 301171

Los Angeles, CA 90030-1171

Online Submissions: www.SpectrumPharmaceuticalsSecuritiesSettlement.com



THIS PAGE INTENTIONALLY LEFT BLANK



EXHIBIT C



1 McInnis Parkway
Suite 250
San Rafael, CA 94903
P: (415) 458-3015

July 3, 2025

«FirstName» «LastName»
«Company»
«Addr1»
«Addr2»
South Bend, IN 46601
«FCountry»

Re: Spectrum Pharmaceuticals Securities Settlement

Dear «GENDER» «LastName»:

Please find enclosed the Postcard Notice for the above-referenced litigation. The full Notice of Pendency and Proposed Settlement of Class Action ("Notice") is available for review and download on the settlement website. Please note both the Class Period and the designated eligible securities described on page one of the full Notice, specifically the inclusion of all persons and entities who purchased or otherwise acquired Spectrum Pharmaceuticals, Inc. ("Spectrum") common stock between March 7, 2018 and August 5, 2021, inclusive. In addition, **the Notice provides that the Exclusion Deadline is September 29, 2025 and the Claim Filing Deadline is October 1, 2025.**

Please pay particular attention to the "Special Notice to Securities Brokers and Other Nominees" on page sixteen of the full Notice which states, in part: Nominees who purchased or acquired Spectrum common stock during the Class Period for beneficial owners who are Class Members are directed to: (i) request within seven (7) calendar days of receipt of the Postcard Notice sufficient copies of the Postcard Notice from the Claims Administrator to forward to all such beneficial owners; or (ii) send a list of the names and addresses (including email addresses if available) of such beneficial owners to the Claims Administrator, at notifications@veritaglobal.com or the address below, within seven (7) calendar days after receipt of the Postcard Notice. If a nominee elects to send the Postcard Notice to beneficial owners, such nominee is directed to email or mail (where an email is unavailable) the Postcard Notice within seven (7) calendar days of receipt of those documents from the Claims Administrator, and upon such emailing or mailing, the nominee shall send a statement to the Claims Administrator confirming that the emailing or mailing was made as directed, and the nominee shall retain the list of names and addresses for use in connection with any possible future notice to the Class.

Additional copies of the appropriate documents may be requested by contacting us at the above address and/or phone number. If we conduct the necessary mailing on your behalf, please submit names and addresses either via email to notifications@veritaglobal.com, via CD Rom to the above address or contact us to obtain secure FTP transmission instructions. Mailing labels will be accepted, but you may be requested to provide an additional copy of the address information you send. Do not include any confidential information that should not appear on a mailing label.

The data provided must be in one of the following formats: ASCII Fixed Length file, ASCII Tab Delimited file, or Microsoft Excel spreadsheet.

Your request must also specify the case name and Control Total(s) (for example, the total number of name and address records provided) for each file submission.

If you have any questions, please email notifications@veritaglobal.com.

Sincerely,
Verita Global

EXHIBIT D

BUSINESS & FINANCE

Ports Seek Tariff Delay on Chinese Cranes

Ship-to-shore cranes made in China face U.S. levies of up to 100%

By PAUL BERGER

U.S. port operators are warning that the cost of critical upgrades would balloon by tens of millions of dollars if the Trump administration moves forward with proposed new tariffs on port equipment.

The administration is proposing tariffs of up to 100% on Chinese-made cranes and other cargo-handling equipment as part of broader efforts to counter China's dominance of the maritime industry. Shipping industry officials say the fees would be stacked on top of 25% tariffs on Chinese-made cranes introduced under the Biden administration, and in addition to China duties being considered by Trump's trade team.

Ports and the private companies that operate marine terminals say the fees would penalize cargo gateways that ordered cranes long before the tariffs were being considered, and don't account for the scarcity of cranes made outside of China.

China's Shanghai Zhenhua Heavy Industries, known as ZPMC, accounts for nearly 80% of ship-to-shore cranes at U.S. ports, dwarfing competitors such as Finland's Konecranes and Germany's Liebherr.

Carl Bentzel, president of the National Association of Waterfront Employers, said he has visited the White House several times to urge senior administration officials to give



The tariffs are being considered by the Office of the U.S. Trade Representative, which conducted an investigation into China's dominance of the maritime industry.

ports more time to find alternative sources for cranes.

"They said, 'We're going to put penalties as high as necessary to ensure you don't buy equipment from China,'" Bentzel said. "But we need some level of transition."

China produces more than 70% of the world's ship-to-shore cranes, according to the U.S. government. Administration officials worry China's control of critical infrastructure is an economic and a national security threat. They also allege some Chinese-

made cranes have been fitted with communications equipment that could be used for espionage.

Chinese cranes are popular because they are plentiful and cheap. Shipping industry officials say the average cost of a Chinese ship-to-shore crane is about \$15 million, several million dollars less than the lowest-price competitors. They say there are no domestic alternatives and that smaller overseas manufacturers wouldn't be able to meet demand if U.S. ports pivot to manufacturers

outside of China.

The tariffs are being considered by the Office of the U.S. Trade Representative, which under President Biden conducted an investigation into China's dominance of the maritime industry.

Charlie Jenkins, chief executive of the Port of Houston, testified at a USTR office hearing earlier this year that based on discussions with crane makers, it would take about a decade to develop sufficient crane manufacturing capacity in the U.S. Jenkins

said that over the next six years his port needs to order 22 cranes with a potential tariff liability of \$100 million.

It can take up to two years to fulfill a crane order. Port operators are asking the administration to provide tariff exemptions for cranes ordered before the end of 2024. They also are asking the USTR's office to delay imposing levies on new crane orders for three years to give time for crane manufacturing to develop in the U.S., or for manufacturers in allied countries to expand

production.

The USTR's office decided earlier this year that starting in mid-October the U.S. will impose fees on owners and operators of Chinese-built ships that call at U.S. ports.

The trade representative's office also is considering imposing fees on foreign-built car carriers that call at U.S. ports. The proposal is opposed by ocean-shipping trade groups. The U.S. Chamber of Commerce warns the fees could reduce vehicle availability and add \$300 to car prices.

ADVERTISEMENT

The Marketplace

To advertise: 800-366-3975 or [WSJ.com/classifieds](https://www.wsj.com/classifieds)

CLASS ACTION

UNITED STATES DISTRICT COURT DISTRICT OF NEVADA	
JOSE CHUNG LUO, Individually and on Behalf of All Others Similarly Situated,	Civil Action No. 2:21-cv-01612-CDS-BNW
Plaintiff,	CLASS ACTION
vs.	SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION
SPECTRUM PHARMACEUTICALS, INC., et al.,	
Defendants.	

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SPECTRUM PHARMACEUTICALS, INC. ("SPECTRUM") COMMON STOCK BETWEEN MARCH 7, 2018, AND AUGUST 5, 2021, INCLUSIVE (THE "CLASS PERIOD")

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Nevada ("Court"), that the above-captioned action ("Litigation") has been certified as a class action, except for certain Persons and entities who are excluded from the Class by definition as set forth in the Stipulation of Settlement dated May 9, 2025 ("Stipulation") and the detailed Notice of Pendency and Proposed Settlement of Class Action ("Notice"). The Stipulation and Notice can be viewed at www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

YOU ARE ALSO HEREBY NOTIFIED that International Trading Group, Inc. ("Lead Plaintiff"), and defendants Spectrum, Joseph W. Turgeon, Kurt A. Gustafson, Francois J. Lebel, and Thomas J. Riga ("Defendants") have reached a proposed settlement of the Litigation on behalf of the Class for \$15.95 million in cash ("Settlement"). If approved by the Court, the Settlement will resolve all claims in the Litigation.

YOU ARE ALSO HEREBY NOTIFIED that a hearing will be held on October 20, 2025, at 10:00 a.m., before the Honorable Cristina D. Silva at the United States District Court, District of Nevada, Lloyd D. George Federal Courthouse, 333 Las Vegas Boulevard South, Las Vegas, NV 89101, to determine whether: (1) the Settlement of the above-captioned Litigation as set forth in the Stipulation for \$15.95 million in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Plaintiff's Counsel attorneys' fees and expenses out of the Settlement Fund (as defined in the Notice) and, if so, in what amounts; and (4) to award Lead Plaintiff its costs and expenses in representing the Class out of the Settlement Fund and, if so, in what amount; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.

The Court may decide to change the date and/or time of the Settlement Hearing, conduct the hearing by video or telephonic conference, or otherwise allow Class Members to appear at the hearing by telephone or videoconference, without further written notice to the Class. It is important that you check the Settlement website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or telephonic appearances at the hearing, will be posted to the Settlement website. Also, if the Court requires or allows Class Members to participate in the hearing by telephone or videoconference, the access information will be posted to the website.

IF YOU PURCHASED OR OTHERWISE ACQUIRED SPECTRUM COMMON STOCK BETWEEN MARCH 7, 2018, AND AUGUST 5, 2021, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

To share in the distribution of the Net Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail (postmarked no later than October 1, 2025) or electronically via the Settlement website (no later than October 1, 2025). Failure to submit your Proof of Claim by October 1, 2025, will subject your claim to rejection and preclude you from receiving any of the recovery in connection with the Settlement of this Litigation. If you are a Class Member and do not request exclusion from the Class (as described below), you will be bound by the Settlement and any judgment and release entered in the Litigation, including, but not limited to, the Judgment, whether or not you submit a Proof of Claim.

The Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement), the Proof of Claim, the Stipulation (which, among other things, contains definitions for the capitalized terms used in this Summary Notice), and other important documents, may be accessed online at www.SpectrumPharmaceuticalsSecuritiesSettlement.com, or by writing to:

Spectrum Pharmaceuticals Securities Settlement
Claims Administrator
c/o Verita Global
P.O. Box 301171
Los Angeles, CA 90030-1171

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim, may be made to Lead Counsel:

ROBBINS GELLER RUDMAN & DOWD LLP
Ellen Gusikoff Stewart
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 1-800-449-4900
settlementinfo@rgdlaw.com

IF YOU DESIRE TO BE EXCLUDED FROM THE CLASS, YOU MUST SUBMIT A REQUEST FOR EXCLUSION NOTICE THAT IT IS POSTMARKED BY SEPTEMBER 29, 2025, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE. IF YOU PROPERLY EXCLUDE YOURSELF FROM THE CLASS, YOU WILL NOT BE BOUND BY ANY RELEASES, JUDGMENTS, OR ORDERS ENTERED BY THE COURT IN THE LITIGATION AND YOU WILL NOT RECEIVE ANY BENEFITS FROM THE SETTLEMENT. EXCLUDING YOURSELF FROM THE CLASS IS THE ONLY OPTION THAT MAY ALLOW YOU TO BE PART OF ANY OTHER CURRENT OR FUTURE LAWSUIT AGAINST DEFENDANTS CONCERNING THE CLAIMS BEING RESOLVED BY THE SETTLEMENT.

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT. THE PLAN OF ALLOCATION, THE REQUEST BY LEAD COUNSEL FOR AN AWARD OF ATTORNEYS' FEES NOT TO EXCEED 30% OF THE \$15.95 MILLION SETTLEMENT AMOUNT AND EXPENSES NOT TO EXCEED \$200,000, PLUS INTEREST ON BOTH AMOUNTS, AND/OR THE REQUEST FOR AN AWARD TO LEAD PLAINTIFF PURSUANT TO 15 U.S.C. §78u-4(a)(4). ANY OBJECTIONS MUST BE FILED WITH THE COURT AND SENT TO LEAD COUNSEL AND DEFENDANTS' COUNSEL BY SEPTEMBER 29, 2025, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: June 16, 2025

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

NOTICE OF SALE

NOTICE OF PUBLIC SALE • Property to be Sold				
Public Sale No. 1:				
Wednesday, July 16 th , 2025 10:00 a.m. EDT				
The Asset Type for Lots 1-2 is ABS CDO; Lots 3-5 is Prime / Alt A; Lots 6-9 is Second Lien; Lots 10-21 is Subprime; and Lots 22-52 is Zero Factor – RBMS.				
Lot #	CUSIP	Issue	Original Face	
1	00081AAE9	ACABS 2003-1A C	5,000,000.00	
2	92533VAD6	VERT 2003-1A C2	5,000,000.00	
3	07386RKH3	BALTA 2004-6 B2	5,500,000.00	
4	437690CR9	HMAC 2004-6 M7	3,327,000.00	
5	437690CS7	HMAC 2004-6 M8	1,173,000.00	
6	22541SR31	HEMT 2004-5 B1	1,575,000.00	
7	78577BD17	SACO 2004-3A B1	2,200,000.00	
8	86359BC41	SASC 2004-53 M7	3,000,000.00	
9	86359BM73	SASC 2004-54 M7	1,500,000.00	
10	00764MA6	AABST 2003-2 M2	3,260,000.00	
11	004421DF7	ACE 2003-HE1 M6	1,000,000.00	
12	040104E01	ARSI 2003-W10 M4	5,000,000.00	
13	07325NAH5	BAIT 2004-9 B2	1,000,000.00	
14	29445FC6	EMIT 2004-3 M8	281,000.00	
15	31659TCS2	FMIC 2004-5 M4	2,750,000.00	
16	31659TCT0	FMIC 2004-5 M5	1,750,000.00	
17	57643FD3	MABS 2004-OPT2 M8	4,000,000.00	
18	589925P9	MLMI 2003-OPT1 B2	2,000,000.00	
19	6174ACZ0	MSAC 2004-HE9 B1	3,000,000.00	
20	86359AZ88	SAIL 2003-BC10 M3	5,000,000.00	
21	861561C04	TMTS 2003-GHE M5	1,350,000.00	
22	04541GN8	ABSH 2004-HE9 M5	2,000,000.00	
23	04541GN5	ABSH 2004-HE9 M6	1,000,000.00	
24	07386HMT5	BALTA 2004-11 B1	2,500,000.00	
25	07386HMT5	BALTA 2004-12 B2	1,200,000.00	
26	073879G19	BSABS 2004-ACS B1	2,252,000.00	
27	073879UW6	BSABS 2004-ACB B3	1,000,000.00	
28	12506GCE7	CDMIC 03-HE4 B2	2,000,000.00	
29	12698P94	CWHL 2004-HYB6 B2	5,757,000.00	
30	12698P96	CWHL 2004-HYB6 B2	5,757,000.00	
31	126673PR2	CWL 2004-12 BV	1,500,000.00	
32	126673MT1	CWL 2004-12 MV7	2,000,000.00	
33	126673R08	CWL 2004-13 BV	1,600,000.00	
34	126673RT1	CWL 2004-13 MV8	2,400,000.00	
35	22541SR60	FFML 04-FB8 B	6,000,000.00	
36	32027NN09	FFML 2004-FB11 M7	1,000,000.00	
37	32027NN09	FFML 2004-FB12 B2	3,182,000.00	
38	32027NNW7	FFML 2004-FB8 B3	1,334,000.00	
39	45254TOK5	IMSA 2004-4 B	1,750,000.00	
40	57643FLV5	MABS 2004-WMC3 M7	1,500,000.00	
41	57643FLV3	MABS 2004-WMC3 M8	1,500,000.00	
42	576433M8B	MARM 2004-4 B3	2,292,000.00	
43	576433P6K	MARM 2004-6 B3	2,867,000.00	
44	576433J0B	MARM 2004-7 B3	1,881,000.00	
45	6174ACB81	NSAC 2004-HE9 B3	1,500,000.00	
46	60987GCB1	NHL 2004-4 B3	1,500,000.00	
47	759950BK5	RAMC 2003-4 M4	2,700,000.00	
48	759950BF1	RAMC 2004-4 MV3	2,000,000.00	
49	76112BC01	RAMP 2004-RS9 M14	4,000,000.00	
50	76110WJ64	RASC 2004-KS11 M4	2,800,000.00	
51	785778DM4	SACO 2004-3A B2	1,402,000.00	
52	863579FH6	SARM 2004-16 B5	4,702,000.00	

Dock Street Capital Management LLC on behalf of Wells Fargo Bank, National Association, in its capacity as trustee ("Trustee"), will be conducting a public sale of certain collateral pledged to the Trustee. The Collateral (as defined herein) will be offered and sold by the Trustee without recourse, representations, or covenants, express or implied, being made by the Trustee with respect to the Collateral (except as to title to the Collateral) or with respect to any other information then in the Trustee's possession, including without limitation any offering circular or other financial information. **Location of Sales:** The sales will be held at 575-B Riverside Avenue, Westport, CT 06880. **Additional Information:** Please be advised that the sale of each security listed above may be made only to the best bidder who is also a qualified bidder and may be subject to a reserve level. For additional information, including with respect to qualified bidder status, and to obtain copies of an Investor Representation and Confidentiality Agreement, contact David Crowle or Jeffrey Holtman by email at dcrowle@dockstreetcap.com or jholtman@dockstreetcap.com, respectively, by phone at (212) 457-8258, by facsimile at (212) 457-8269 or by mail addressed to 575-B Riverside Avenue, Westport, CT 06880. **Disclaimer:** The Trustee is authorized at such sale, if the Trustee deems it advisable or is required by applicable law to do so: (i) to restrict the prospective bidders on or purchasers of any of the above identified securities (the "Collateral") to be sold to those who will represent and agree that they are purchasing for their own account for investment and not with a view to the distribution or resale of any of such assets, (ii) to verify that each certificate for each security to be sold that has not been registered under the Securities Act of 1933 bears a legend substantially to the effect that such security has not been registered under the Securities Act of 1933, as amended, and may not be disposed of in violation of the provisions of said Act, (iii) to disclaim and to refuse to give any warranty (other than as to title), and (iv) to impose such other limitations or conditions in connection with any such sale as the Trustee deems necessary or advisable.

PUBLIC NOTICES

ACM Delegate LLC ("ACM"), as secured party and agent for certain lenders, will conduct a public foreclosure sale pursuant to Section 9-410 of the Uniform Commercial Code, as in effect in the State of New York, on July 16, 2025, commencing at 10:00 a.m., Mountain time (or as continued at that time), and at the offices of Dorsy & Whitney LLP, at 1400 Wewatta St., Suite 400, Denver, Colorado 80202-5549. This is a public auction of personal property assets pledged to ACM, as agent, by Lolli & Pops Holdings, LLC and Hammond's Candies Since 1920 II, LLC, collectively a confectionery retail and manufacturing company. Bidders wishing to register and qualify to bid must contact counsel to the Secured Party: John O. Sutton, Jr., Dorsy & Whitney LLP at sutton.john@dorsy.com or (214) 981-9922 prior to the commencement of the auction.



Vie Ventures co-founders Luke Evnin, left, and Steven St. Peter.

New Fund to Target Biotech Focused on Autoimmune Diseases

By BRIAN GORMLEY

Two veteran life-sciences investors have launched Vie Ventures, which plans to fund biotechnology startups targeting autoimmune diseases and connect them with nonprofits that might accelerate their drug development.

Vie co-founders Luke Evnin and Dr. Steven St. Peter previously invested together with MPM Capital, now MPM BioImpact. Both also have experience with nonprofits: Evnin is chairman of the Scleroderma Research Foundation and St. Peter most recently was managing director of the T1D

Fund, the venture-philanthropy arm of Breakthrough T1D, which supports Type 1 diabetes research. While some disease-focused nonprofits have venture arms, they typically lack the scale of an established venture-capital firm. In addition, biotech companies often develop drugs for more than one autoimmune disease. As a result, Evnin and St. Peter said they saw an opportunity for a venture firm to invest broadly in autoimmune and other immune disorders.

By working with nonprofits, biotech companies can gain access to resources such as scientific expertise and understanding of the regulatory landscape. Vie has built a coalition of nonprofits, including the Scleroderma Research Foundation and the National Multiple Sclerosis Society, with a goal of knitting together expertise in these diseases, said Evnin, a

senior adviser to Vie.

One benefit of collaboration is that immunological mechanisms involved in one autoimmune disease may also affect others, leading to insights that aid drug development in various conditions, said Tim Coetzee, president and chief executive of the multiple sclerosis society. "There is crossover biology in the immune system," he said.

Nonprofits also can help investors and biotech companies understand issues such as how the design of a clinical trial affects patients' ability to participate in the study, Coetzee said.

Vie, which was founded in February, aims to secure \$75 million in a first closing of the fund by year-end, said St. Peter, who is managing director of the firm. Several venture firms launch biotech, but Vie intends

to focus instead of those raising their second or third rounds of funding. "There's a gap in the market for people willing to lead deals in a Series B or C," St. Peter said.

Biotech venture capital generally has retreated this year as initial public offerings in the sector have slumped. More capital is needed to fund start-ups advancing promising research in autoimmune diseases, said Louis DeGennaro, former president and CEO of the Leukemia & Lymphoma Society and now a senior adviser to Vie.

"There are companies that have good agents and good science that are wanting for investment," he added.

THE WALL STREET JOURNAL.

THE MARKETPLACE

ADVERTISE TODAY | (800) 366-3975 | [wsj.com/classifieds](https://www.wsj.com/classifieds)

© 2025 Dow Jones & Company, Inc. All Rights Reserved.

DOW JONES

Declaration of Publication

I, Carla Peak, as Vice President, Legal Notification Services at Verita Global LLC f/k/a Gilardi Settlement Administration Company in San Rafael, California, hereby certify that I caused the attached notice to be printed in said publication on July 10, 2025:

Name of Publication: The Wall Street Journal

Address: 1211 Avenue of the Americas

City, State, Zip: New York, NY 10036

Phone #: 1-800-568-7625

State of: New York

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 10th day of July 2025, at Sellersville, Pennsylvania.

A handwritten signature in black ink, appearing to read "Carla Peak", written over a horizontal line.

Carla Peak

Robbins Geller Rudman & Dowd LLP Announces Proposed Settlement in the Spectrum Pharmaceuticals, Inc. Litigation

ROBBINS GELLER RUDMAN & DOWD LLP

✓ NASDAQ-SPPI

Share      ...

RELEASE VERSIONS

English

CONTACTS

Media:
Robbins Geller Rudman & Dowd LLP
Shareholder Relations Department
Greg Wood
(619) 231-1058

SAN DIEGO--(BUSINESS WIRE)--The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the proposed Settlement in the Spectrum Pharmaceuticals, Inc. Litigation:

UNITED STATES DISTRICT COURT DISTRICT OF NEVADA

JOSE CHUNG LUJO, Individually and on Behalf of All Others Similarly Situated,

Civil Action No. 2:21-cv-01612-CDS-BNW

Plaintiff,

vs.

SPECTRUM PHARMACEUTICALS, INC., et al

Defendants.

CLASS ACTION

SUMMARY NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF
CLASS ACTION

TO: ALL PERSONS OR ENTITIES WHO PURCHASED OR OTHERWISE ACQUIRED SPECTRUM PHARMACEUTICALS, INC. ("SPECTRUM") COMMON STOCK BETWEEN MARCH 7, 2018, AND AUGUST 5, 2021, INCLUSIVE (THE "CLASS PERIOD")

THIS NOTICE WAS AUTHORIZED BY THE COURT. IT IS NOT A LAWYER SOLICITATION. PLEASE READ THIS NOTICE CAREFULLY AND IN ITS ENTIRETY.

YOU ARE HEREBY NOTIFIED, pursuant to Rule 23 of the Federal Rules of Civil Procedure and an Order of the United States District Court for the District of Nevada ("Court"), that the above-captioned action ("Litigation") has been certified as a class action, except for certain Persons and entities who are excluded from the Class by definition as set forth in the Stipulation of Settlement dated May 9, 2025 ("Stipulation") and the detailed Notice of Pendency and Proposed Settlement of Class Action ("Notice"). The Stipulation and Notice can be viewed at www.SpectrumPharmaceuticalsSecuritiesSettlement.com.

YOU ARE ALSO HEREBY NOTIFIED that International Trading Group, Inc. ("Lead Plaintiff"), and defendants Spectrum, Joseph W. Turgeon, Kurt A. Gustafson, Francois J. Lebel, and Thomas J. Riga ("Defendants") have reached a proposed settlement of the Litigation on behalf of the Class for \$15.95 million in cash ("Settlement"). If approved by the Court, the Settlement will resolve all claims in the Litigation.

YOU ARE ALSO HEREBY NOTIFIED that a hearing will be held on October 20, 2025, at 10:00 a.m., before the Honorable Cristina D. Silva at the United States District Court, District of Nevada, Lloyd D. George Federal Courthouse, 333 Las Vegas Boulevard South, Las Vegas, NV 89101, to determine whether: (1) the Settlement of the above-captioned Litigation as set forth in the Stipulation for \$15.95 million in cash should be approved by the Court as fair, reasonable, and adequate; (2) the Judgment as provided under the Stipulation should be entered dismissing the Litigation with prejudice; (3) to award Lead Plaintiff's Counsel attorneys' fees and expenses out of the Settlement Fund (as defined in the Notice) and, if so, in what amounts; (4) to award Lead Plaintiff its costs and expenses in representing the Class out of the Settlement Fund and, if so, in what amount; and (5) the Plan of Allocation should be approved by the Court as fair, reasonable, and adequate.

The Court may decide to change the date and/or time of the Settlement Hearing, conduct the hearing by video or telephonic conference, or otherwise allow Class Members to appear at the hearing by telephone or videoconference, without further written notice to the Class. It is important that you check the Settlement website, www.SpectrumPharmaceuticalsSecuritiesSettlement.com, before making any plans to attend the Settlement Hearing. Any updates regarding the Settlement Hearing, including any changes to the date or time of the hearing or updates regarding in-person or telephonic appearances at the hearing, will be posted to the Settlement website. Also, if the Court requires or allows Class Members to participate in the hearing by telephone or videoconference, the access information will be posted to the website.

IF YOU PURCHASED OR OTHERWISE ACQUIRED SPECTRUM COMMON STOCK BETWEEN MARCH 7, 2018, AND AUGUST 5, 2021, INCLUSIVE, YOUR RIGHTS ARE AFFECTED BY THE SETTLEMENT OF THIS LITIGATION.

To share in the distribution of the Net Settlement Fund, you must establish your rights by submitting a Proof of Claim and Release form ("Proof of Claim") by mail (postmarked no later than October 1, 2025) or electronically via the Settlement website (no later than October 1, 2025). Failure to submit your Proof of Claim by October 1, 2025, will subject your claim to rejection and preclude you from receiving any of the recovery in connection with the Settlement of this Litigation. If you are a Class Member and do not request exclusion from the Class (as described below), you will be bound by the Settlement and any judgment and release entered in the Litigation, including, but not limited to, the Judgment, whether or not you submit a Proof of Claim.

The Notice, which more completely describes the Settlement and your rights thereunder (including your right to object to the Settlement), the Proof of Claim, the Stipulation (which, among other things, contains definitions for

Spectrum Pharmaceuticals Securities Settlement

Claims Administrator
c/o Verita Global
P.O. Box 301171
Los Angeles, CA 90030-1171

Inquiries should NOT be directed to Defendants, the Court, or the Clerk of the Court.

Inquiries, other than requests for the Notice or for a Proof of Claim, may be made to Lead Counsel:

ROBBINS GELLER RUDMAN & DOWD LLP

Ellen Gusikoff Stewart
655 West Broadway, Suite 1900
San Diego, CA 92101
Telephone: 1-800-449-4900
settlementinfo@rgrdlaw.com

IF YOU DESIRE TO BE EXCLUDED FROM THE CLASS, YOU MUST SUBMIT A REQUEST FOR EXCLUSION SUCH THAT IT IS **POSTMARKED BY SEPTEMBER 29, 2025**, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE. IF YOU PROPERLY EXCLUDE YOURSELF FROM THE CLASS, YOU WILL NOT BE BOUND BY ANY RELEASES, JUDGMENTS, OR ORDERS ENTERED BY THE COURT IN THE LITIGATION AND YOU WILL NOT RECEIVE ANY BENEFITS FROM THE SETTLEMENT. EXCLUDING YOURSELF FROM THE CLASS IS THE ONLY OPTION THAT MAY ALLOW YOU TO BE PART OF ANY OTHER CURRENT OR FUTURE LAWSUIT AGAINST DEFENDANTS CONCERNING THE CLAIMS BEING RESOLVED BY THE SETTLEMENT.

IF YOU ARE A CLASS MEMBER, YOU HAVE THE RIGHT TO OBJECT TO THE SETTLEMENT, THE PLAN OF ALLOCATION, THE REQUEST BY LEAD COUNSEL FOR AN AWARD OF ATTORNEYS' FEES NOT TO EXCEED 30% OF THE \$15.95 MILLION SETTLEMENT AMOUNT AND EXPENSES NOT TO EXCEED \$200,000, PLUS INTEREST ON BOTH AMOUNTS, AND/OR THE REQUEST FOR AN AWARD TO LEAD PLAINTIFF PURSUANT TO 15 U.S.C. §78u-4(a) (4). ANY OBJECTIONS MUST BE FILED WITH THE COURT AND SENT TO LEAD COUNSEL AND DEFENDANTS' COUNSEL **BY SEPTEMBER 29, 2025**, IN THE MANNER AND FORM EXPLAINED IN THE NOTICE.

DATED: June 16, 2025

BY ORDER OF THE COURT
UNITED STATES DISTRICT COURT
DISTRICT OF NEVADA

Contacts

Media:
Robbins Geller Rudman & Dowd LLP
Shareholder Relations Department
Greg Wood
(619) 231-1058

Declaration of Publication

I, Carla Peak, as Vice President, Legal Notification Services at Verita Global LLC f/k/a Gilardi Settlement Administration Company in San Rafael, California, hereby certify that I caused the attached notice to be published as a press release by the following wire service:

Name of Publication: BusinessWire

Address: 101 California Street 20th Floor

City, ST Zip: San Francisco, CA 94111

Phone #: 415-986-4422

State of: California

The press release was distributed on July 10, 2025 to the following media circuits offered by the above-referenced wire service:


1. National Newslne

I declare under penalty of perjury that the foregoing is true and correct. Executed on this 10th day of July 2025, at Sellersville, Pennsylvania.

A handwritten signature in black ink that reads "Carla Peak". The signature is written in a cursive, flowing style. Below the signature is a horizontal line.

Carla Peak

EXHIBIT E

 *SPPS-EXCL00001*
██
██
██
██

RECEIVED
September 8, 2025
Claims Center

Exclusion Cover Page

Case Name: Spectrum Pharmaceuticals Securities Settlement

Case Code: SPPS

Exclusion Deadline: September 29, 2025 (Postmarked)

Name of Person Filing Exclusion: Raquel Claudia Cahill

Spectrum Pharmaceuticals Securities Settlement

Claims Administrator

c/o Verita Global

EXCLUSIONS

P.O. Box 5100

LARKSPUR , CA 94977-5100


Dear Court administrator

I received a post card notice re: Class Action of SPPS

I would like to be **EXCLUDED** from any Class action please .

My details are:

RAQUEL CLAUDIA CAHILL



Please kindly knowledge and confirm the exclusion.

Thank you and Rgs

A handwritten signature in cursive script, appearing to read 'Raquel R. Cahill'.



Spectrum Pharmaceuticals Securities Settlement

Claims Administrator

c/o Verita Global

EXCLUSIONS



P.O. Box 5100

Larkspur, CA 94977-5100

RECEIVED
SEP 08 2025

BY:

U.S.A.
49775100 B014



R.O. PAHLL